Pacira Biosciences Stock PCRX
Pacira BioSciences is a specialty pharmaceutical company focused on non-opioid pain management and regenerative medicine for patients in surgical, interventional, and musculoskeletal care settings. Pacira Biosciences stock (PCRX): Quarterly and annual results since 2023 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 08/2026, quarterly reporting. Stock analysis by NadirAlpha. Pacira Biosciences stock (PCRX): listed on Nasdaq. NadirAlpha has evaluated 53 original documents, cross-checked every figure automatically and linked each to its source; sources as of 08/2026. Revenue Q2 2026: USD 192 million (+6% year on year). Latest reported (Q2 2026): ZILRETTA net selling price growth, ZILRETTA kit volume growth, EXPAREL net selling price change. Latest reading: Divestiture, Cash flow inflection, New market.
strategy: Divestiture Cash flow inflection strategy: New market
The new quarter, monitored by AI. · NadirAlpha follows every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.
Pacira Biosciences Current Status
Where Pacira Biosciences stands after the report for Q2 2026: what changed in revenue, earnings and outlook, written editorially from the original report. NadirAlpha methodology
Assessment by NadirAlpha, as of Q2 2026.
Pacira BioSciences reported second-quarter 2026 total revenue of 192.4 million, representing 6 percent year-over-year growth, with EXPAREL net product sales of $147.8 million (up 3 percent year-over-year), ZILRETTA net product sales of $32.6 million (up 4 percent), and iovera° net product sales of $6.8 million (up 22 percent) 34. GAAP net income was 4.7 million (0.12 per diluted share), compared with a net loss of 4.8 million in the prior year quarter 34. Subsequent to the quarter, Pacira completed the divestiture of its iovera° business to Zimmer Biomet on July 31, 2026 and UnitedHealthcare began providing separate reimbursement for EXPAREL across outpatient settings 33.
Management commentary on the 2026-Q2 results (8-K-EX99.1, 2026-08-04):
“The first half of 2026 was marked by solid revenue growth and strong execution of our 5x30 strategy across the business. Just 18 months into the initiative, we are delivering meaningful progress against each of our strategic objectives to drive long-term growth and create significant value. The quarter was also highlighted by our recently closed transaction with Zimmer Biomet, which positions iovera° to reach its full global potential while preserving Pacira's participation in its future success and further sharpening our focus as an innovation-driven biopharmaceutical company.”
Revenue · 2026-Q2192$ million+6.2 % vs. 2025-Q2
Net profit · 2026-Q25$ million+197.9 % vs. 2025-Q2
EPS · 2026-Q20.12$+209.1 % vs. 2025-Q2
Revenue trend
Guidance
For FY2026, Pacira Biosciences guides Revenue 735 to 760 $ million (cut); Non-GAAP SG&A expense 310 to 330 $ million (cut); Stock-based compensation 54 to 59 $ million (cut). 34 Longer-term target for FY2030: Gross margin (GAAP) Five percentage point gross margin improvement over 2024 (initiated). 19
ProfitabilityPacira reported GAAP operating income of 4.3 million for the second quarter, alongside non-GAAP net income of $29.5 million, or 0.73 per diluted share, compared with non-GAAP net income of $36.0 million ($0.74 diluted) in the prior year period 34. A discrete tax benefit of $6.4 million was recorded during the quarter from the reversal of the UK operating subsidiary's valuation allowance, based on improved realizability of deferred tax assets 33. Free cash flow for the quarter was 56.1 million, on operating cash flow of 57.5 million less capital expenditures of 1.3 million.
LeveragePacira ended the second quarter with cash and cash equivalents of 205.9 million and net debt of 157.2 million, reduced from 223.3 million at the close of the prior quarter. Net debt in the year-ago quarter was 280 million. The period-end cash balance does not yet reflect upfront proceeds from the iovera° divestiture completed on July 31, 2026 33.
Management viewUnitedHealthcare began providing separate reimbursement for EXPAREL across outpatient settings in July 2026, expanding access to approximately 150 million covered lives in the U.S. 33. Pacira's partnership with LG Chem for exclusive EXPAREL commercialization rights in select Asian-Pacific markets, established in January 2026, is expected to begin generating revenue in 2027 33. Part A of the Phase 2 ASCEND study for PCRX-201 completed enrollment during the quarter, with topline data expected by end of 2026, advancing the company's HCAd-based gene therapy candidate for osteoarthritis 33.
ChangeGross margin was flat year-over-year at 77% for the second quarter, as higher EXPAREL product costs from lower production volumes were substantially offset by fewer inventory reserves; on a six-month basis, gross margin decreased one percentage point to 78% 33. Research and development expense increased 7% in the second quarter, with increased investment in the HCAd platform partially offset by lower clinical and preclinical spending as multiple trial enrollments were completed 33. Selling, general and administrative expense increased 4% in the quarter, driven by expanded market access and reimbursement teams and increased business development headcount 33.
Risks (current)Two Chinese generic manufacturers filed ANDA applications for a generic version of EXPAREL, and Pacira is engaged in patent infringement litigation filed in November 2025 to defend its intellectual property 33. U.S. government tariffs on certain pharmaceutical products and active pharmaceutical ingredients imported from multiple jurisdictions are expected to increase manufacturing and input costs and negatively impact gross margins 33. PCRX-201's path to market depends on successful completion of the Phase 2 ASCEND trial, regulatory approval, and commercialization, with manufacturing recently transitioned to a new platform requiring validation; ZILRETTA expansion to the shoulder osteoarthritis indication remains contingent on Phase 3 trial success and regulatory approval 33.
New this reporting periodPacira completed the divestiture of its iovera° cryoanalgesia business to Zimmer Biomet on July 31, 2026 for an upfront cash payment of $73.6 million, with potential revenue-based milestone payments of up to $70.0 million through 2031 33. ZILRETTA's Phase 3 trial for shoulder osteoarthritis completed enrollment in April 2026 33, and PCRX-201 manufacturing was transitioned to a U.S.-based scalable commercial manufacturing process in July 2026, with Part B of the Phase 2 ASCEND study subsequently underway 33. Thomas Wiggans was elected to the board of directors in June 2026, bringing over 40 years of life sciences leadership experience 33.
Pacira Biosciences Stock: Key Figures ($ million)
NadirAlpha shows fiscal years, half-years and quarters of Pacira Biosciences one below the other, most recently Q2 2026; every figure is clickable and leads to raw value, location and source. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Revenue ($ million) · annual basis, as reported
Net income ($ million) · annual basis, as reported
EPS ($) · annual basis, as reported
Operating cash flow ($ million) · annual basis, as reported
Revenue ($ million) · quarterly basis, as reported
Net income ($ million) · quarterly basis, as reported
EPS ($) · quarterly basis, as reported
Operating cash flow ($ million) · quarterly basis, as reported
Cash ($ million) · annual basis, as reported
Debt ($ million) · annual basis, as reported
Net Debt ($ million) · annual basis, as reported
Capex ($ million) · annual basis, as reported
FCF ($ million) · annual basis, as reported
D&A ($ million) · annual basis, as reported
Cash ($ million) · quarterly basis, as reported
Debt ($ million) · quarterly basis, as reported
Net Debt ($ million) · quarterly basis, as reported
Capex ($ million) · quarterly basis, as reported
FCF ($ million) · quarterly basis, as reported
D&A ($ million) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2016 is on record.
Fiscal years
Amounts in $ million · EPS in $ per share · as reported
| Period | Revenue | Op. income | Net income | EPS ($) | EBITDA (adj.) | OCF | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 726.4 | 19.2 | 7 | 0.16 | 186.5 | 152 | 130 |
| FY2024 | 701 | -73.4 | -99.6 | -2.15 | – | 189.4 | 121 |
| FY2023 | 675 | 87.7 | 42 | 0.89 | 0.21 | 154.6 | 10 |
Quarters
Amounts in $ million · EPS in $ per share · as reported
| Period | Published | Revenue | Op. income | Net income | EPS ($) | EPS adj. ($) | EBITDA (adj.) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-08-04 | 192.4 | 4.3 | 4.7 | 0.12 | 0.73 | 48.7 | 56.1 | 205.9 | 157.2~ | 134 |
| 2026-Q1* | 2026-04-30 | 177.4 | 6.9 | 2.9 | 0.07 | 0.60 | 40.2 | 23 | 144.3 | 223.3~ | 31 |
| 2025-Q4* | 2026-01-08 | 196.9 | 2.3 | 1.6 | 0.04*≈ | – | 38.7 | 43.5 | 158.5 | 213.6 | 28 |
| 2025-Q3* | 2025-11-06 | 179.5 | 6.4 | 5.4 | 0.12 | 0.72 | 49.4 | 57 | 147.6 | 229.1 | 127 |
| 2025-Q2* | 2025-08-05 | 181.1 | 8.5 | -4.8 | -0.11 | – | 54.3 | 9.3 | 300.5 | 280 | 125 |
| 2025-Q1* | 2025-05-08 | 168.9 | 2 | 4.8 | 0.10 | – | 44.1 | 26.9 | 283.6 | 299.8 | 22 |
| 2024-Q4* | 2025-01-10 | 187.3 | 24.7 | 16 | 0.35*≈ | – | 0.06 | 31 | 276.8 | 308.5 | 19 |
| 2024-Q3* | 2024-11-06 | 168.6 | -139.5 | -143.5 | -3.11 | – | 54.7 | 49.8 | 246 | 62.5 | 118 |
| 2024-Q2* | 2024-07-30 | 178 | 28.2 | 18.9 | 0.39 | – | 62.12 | 51.6 | 247.1 | -137.3 | 116 |
| 2024-Q1* | 2024-05-07 | 167.1 | 13.2 | 9 | 0.19 | – | 44.6 | 46.3 | 184.1 | -62.9 | 13 |
| 2023-Q4* | 2024-01-04 | 181.2 | 33.2 | 24.9 | 0.53*≈ | – | 0.07 | 45.8 | 153.3 | 369.1 | 10 |
| 2023-Q3* | 2023-11-02 | 163.9 | 17.7 | 10.9 | 0.23 | – | 52.9 | 41 | 99.1 | 27.5 | 109 |
| 2023-Q2* | 2023-08-02 | 169.5 | 39.9 | 25.8 | 0.51 | – | 54.3 | 40.1 | 86.8 | 56.7 | 107 |
| 2023-Q1* | 2023-05-03 | 160.3 | -3.1 | -19.5 | -0.43 | – | 0.04 | 12.6 | 35.5 | 102~ | 4 |
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Columns not reported in this reporting cadence are hidden: Op. income (adj.) (not reported in any source for these periods).
Pacira Biosciences Balance Sheet & Cash Flow ($ million)
NadirAlpha places cash, debt, operating cash flow and investments of Pacira Biosciences side by side per period, balance sheet values as of the period end, flow items for the period. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
Fiscal years
Amounts in $ million · as reported
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2026-02-26 | 158.5 | 372.2 | 213.6 | 91 | 152 | 15.3 | 136.7 | 130 |
| FY2024 | 2025-02-27 | 276.8 | 585.3 | 308.5 | 78.8 | 189.4 | 10.6 | 178.8 | 121 |
| FY2023 | 2024-01-04 | 153.3 | 522.4 | 369.1 | 75.6 | 154.6 | 15.2 | 139.5 | 10 |
Quarters
Amounts in $ million · as reported
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-08-04 | 205.9 | 363.1~ | 157.2~ | 21.3 | 57.5 | 1.3 | 56.1 | 134 |
| 2026-Q1 | 2026-04-30 | 144.3 | 367.7~ | 223.3~ | 21.3 | 25.7 | 2.7 | 23 | 31 |
| 2025-Q4 | 2026-02-26 | 158.5 | 372.2 | 213.6 | 21.3 | 43.7 | 0.2 | 43.5 | 130 |
| 2025-Q3 | 2025-11-06 | 147.6 | 376.7 | 229.1 | 21.2 | 60.8 | 3.9 | 57 | 127 |
| 2025-Q2 | 2025-08-05 | 300.5 | 580.5 | 280 | 27.3 | 12 | 2.7 | 9.3 | 125 |
| 2025-Q1 | 2025-05-08 | 283.6 | 583.4 | 299.8 | 21.2 | 35.5 | 8.5 | 26.9 | 22 |
| 2024-Q4 | 2025-02-27 | 276.8 | 585.3 | 308.5 | 21.2 | 33.1 | 2.1 | 31 | 121 |
| 2024-Q3 | 2024-11-06 | 246 | 308.5 | 62.5 | 20.3 | 53.9 | 4.1 | 49.8 | 118 |
| 2024-Q2 | 2024-07-30 | 247.1 | 109.8 | -137.3 | 18.8 | 53.2 | 1.6 | 51.6 | 116 |
| 2024-Q1 | 2024-05-07 | 184.1 | 121.1 | -62.9 | 18.4 | 49.1 | 2.8 | 46.3 | 13 |
| 2023-Q4 | 2024-01-04 | 153.3 | 522.4 | 369.1 | 18.5 | 47.6 | 1.8 | 45.8 | 10 |
| 2023-Q3 | 2023-11-02 | 99.1 | 126.6 | 27.5 | 18.4 | 44.4 | 3.4 | 41 | 109 |
| 2023-Q2 | 2023-08-02 | 86.8 | 143.5 | 56.7 | 19 | 43.5 | 3.4 | 40.1 | 107 |
| 2023-Q1 | 2023-05-03 | 35.5 | 137.5~ | 102~ | 19.6 | 19.1 | 6.6 | 12.6 | 4 |
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.
Pacira Biosciences Guidance Tracking (latest per metric/period · 14/26)
All forecasts (guidance) of the Pacira Biosciences management and their later outcome: per metric and period the most recent statement applies, the status is checked against the reported actuals. NadirAlpha methodology
Actuals: revenue in $m
Direction: confirmedcutinitiatedraised Verdict: in linepending
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2030 | 2025-01-10 | Gross margin (GAAP) | Five percentage point gross margin improvement over 2024 | – | 19 | ||
| FY2026 | 2026-08-04 | Revenue | 735–760 | – | 34 | ||
| FY2026 | 2026-08-04 | Non-GAAP SG&A expense | 310–330 | – | 34 | ||
| FY2026 | 2026-08-04 | Stock-based compensation | 54–59 | – | 34 | ||
| FY2026 | 2026-04-30 | Non-GAAP research and development expense | 105–115 | – | 32 | ||
| FY2026 | 2026-04-30 | Non-GAAP selling, general and administrative expense | 320–340 | – | 32 | ||
| FY2026 | 2026-02-26 | Gross margin (non-GAAP) | 77–79% | – | 34 | ||
| FY2026 | 2026-02-26 | EXPAREL net product sales | 600–620 | – | 34 | ||
| FY2026 | 2026-02-26 | Non-GAAP R&D expense | 105–115 | – | 34 | ||
| FY2025 | 2025-11-06 | Revenue | 725–735 | 726.4 | 27 | ||
| FY2025 | 2025-11-06 | Gross margin (non-GAAP) | 80–82% | – | – | 27 | |
| FY2025 | 2025-11-06 | Non-GAAP R&D expense | 95–105 | – | – | 27 | |
| FY2025 | 2025-11-06 | Non-GAAP SG&A expense | 310–320 | – | – | 27 | |
| FY2025 | 2025-11-06 | Stock-based compensation | 56–59 | – | – | 27 | |
| FY2024 | 2024-02-29 | Revenue | 680–705 | 701 | 16 | ||
| FY2024 | 2024-02-29 | Gross margin (non-GAAP) | 74–76% | – | – | 18 | |
| FY2024 | 2024-02-29 | Non-GAAP R&D expense | 70–80 | – | – | 18 | |
| FY2024 | 2024-02-29 | Non-GAAP SG&A expense | 245–265 | – | – | 18 | |
| FY2024 | 2024-02-29 | Stock-based compensation | 50–55 | – | – | 18 | |
| FY2023 | 2023-11-02 | EXPAREL net product sales | 535–540 | – | – | 9 | |
| FY2023 | 2023-08-02 | Gross margin (non-GAAP) | 73–74% | – | – | 9 | |
| FY2023 | 2023-08-02 | ZILRETTA net product sales | 110–115 | – | – | 9 | |
| FY2023 | 2023-08-02 | Stock-based compensation | 46–49 | – | – | 9 | |
| FY2023 | 2023-02-28 | iovera° net product sales | 17–20 | – | – | 5 | |
| FY2023 | 2023-02-28 | Non-GAAP R&D expense | 70–80 | – | – | 5 | |
| FY2023 | 2023-02-28 | Non-GAAP SG&A expense | 220–230 | – | – | 5 |
Pacira Biosciences Stock: Price & Chart
Price history of Pacira Biosciences stock (PCRX) as a TradingView chart, loaded only after a click, alongside the trend of the key figures from the tables. NadirAlpha methodology
Daily candles with news and earnings markers. Loads only on click.
Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.
Pacira Biosciences Event Timeline
This timeline collects the material events of Pacira Biosciences from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements, grouped by quarter. NadirAlpha methodology
Overview: one dot per event · click jumps to the period
2026 · 8 events
earnings 2026-08-04
GAAP net income of USD 4.7 million (0.12 per diluted share) in Q2 2026 versus a net loss of $4.8 million in Q2 2025, aided by a discrete tax benefit of $6.4 million 34
GAAP net income of USD 4.7 million (0.12 per diluted share) in Q2 2026 versus a net loss of $4.8 million in Q2 2025, aided by a discrete tax benefit of $6.4 million 34
Divestiture 2026-08-04
Divestiture of iovera° to Zimmer Biomet completed July 31, 2026 for $73.6 million upfront with potential milestone payments up to $70 million through 2031 33
Divestiture of iovera° to Zimmer Biomet completed July 31, 2026 for $73.6 million upfront with potential milestone payments up to $70 million through 2031 33
New market 2026-08-04
UnitedHealthcare began providing separate reimbursement for EXPAREL across outpatient settings, expanding access to approximately 150 million covered lives in the U.S. 33
UnitedHealthcare began providing separate reimbursement for EXPAREL across outpatient settings, expanding access to approximately 150 million covered lives in the U.S. 33
Cash flow inflection 2026-08-04
Operating cash flow reached USD 57.5 million vs USD 12.0 million in 2025-Q2 (×4.8). 134
Operating cash flow reached USD 57.5 million vs USD 12.0 million in 2025-Q2 (×4.8). 134
“Pacira entered 2026 with strong momentum as our 5x30 strategy continues to generate clear and measurable results. In the first quarter, we delivered solid topline performance, highlighted by renewed growth across our commercial portfolio. This performance is fueled by a powerful combination of expanding market access, growing awareness and adoption, and mounting real world evidence, all of which are reinforcing each other.”
revenue 2026-04-30
Total revenue of USD 177.4 million in Q1 2026, a 5% increase year-over-year, with EXPAREL up 5%, ZILRETTA up 15% and iovera° up 21% 32
Total revenue of USD 177.4 million in Q1 2026, a 5% increase year-over-year, with EXPAREL up 5%, ZILRETTA up 15% and iovera° up 21% 32
Guidance confirmed 2026-04-30
Full-year 2026 guidance reiterated: EXPAREL net product sales of $600 to $620 million and total revenues of $745 to $770 million 32
Full-year 2026 guidance reiterated: EXPAREL net product sales of $600 to $620 million and total revenues of $745 to $770 million 32
Regulation 2026-04-30
PCRX-201 received RMAT designation from FDA and ATMP designation from EMA, enabling expedited development pathways for the HCAd gene therapy platform 31
PCRX-201 received RMAT designation from FDA and ATMP designation from EMA, enabling expedited development pathways for the HCAd gene therapy platform 31
Operating income doubled 2026-04-30
Operating income more than doubled YoY (2.0 to USD 6.9 million, +245%). 31
Operating income more than doubled YoY (2.0 to USD 6.9 million, +245%). 31
2025 · 18 events
Operating income turned positive
Operating income turned positive for the first time after 1 negative fiscal year (-73.4 to +USD 19.2 million). 130
Operating income turned positive for the first time after 1 negative fiscal year (-73.4 to +USD 19.2 million). 130
Net income turned positive
Net income turned positive for the first time after 1 negative fiscal year (-99.6 to +USD 7.0 million). 130
Net income turned positive for the first time after 1 negative fiscal year (-99.6 to +USD 7.0 million). 130
“2025 was a year of disciplined execution for Pacira. With the launch of our 5x30 strategy, we reignited momentum across the business and delivered strong, measurable progress. Our products benefitted more than 2.5 million patients, generated $726 million in revenue, and achieved the highest gross margins in our company's history. Together, these results clearly validate the impact and promise of our 5x30 strategy.”
“We closed 2025 having achieved another year of solid execution and meaningful progress advancing our 5x30 strategic priorities, leaving us well-positioned for sustainable, long-term success. Strong EXPAREL volume growth in the second half of the year underscores the value of our commercial investments and positions us for significant and sustainable revenues moving forward. We enter 2026 with momentum that provides us with a strong foundation and clear line of sight to further operational progress and an exciting chapter of growth ahead.”
earnings 2026-02-26
Full-year GAAP net income of $7.0 million vs. net loss of $99.6 million in 2024; prior-year loss reflected $163.2 million goodwill impairment from FDA approval of a generic EXPAREL competitor and a patent invalidation ruling, not operational deterioration 29
Full-year GAAP net income of $7.0 million vs. net loss of $99.6 million in 2024; prior-year loss reflected $163.2 million goodwill impairment from FDA approval of a generic EXPAREL competitor and a patent invalidation ruling, not operational deterioration 29
Margin expanding 2026-02-26
Full-year 2025 gross margin reached 79%, described as the highest level in the company's history, driven by manufacturing efficiencies and lower EXPAREL inventory reserves 30
Full-year 2025 gross margin reached 79%, described as the highest level in the company's history, driven by manufacturing efficiencies and lower EXPAREL inventory reserves 30
Operating income halved 2026-02-26
Operating income more than halved YoY (24.7 to USD 2.3 million, -91%). 130
Operating income more than halved YoY (24.7 to USD 2.3 million, -91%). 130
revenue 2026-01-08
Q4 EXPAREL net product sales reached $155.8 million with 7% volume growth, the strongest quarterly performance in three years 28
Q4 EXPAREL net product sales reached $155.8 million with 7% volume growth, the strongest quarterly performance in three years 28
“Pacira delivered another quarter of strong execution across our corporate, clinical, and commercial initiatives, underscoring the momentum behind our 5x30 growth strategy. With accelerating topline growth, expanding market access, and meaningful pipeline advancements, including the in-licensing of AMT-143, we believe we are well positioned to expand our leadership in musculoskeletal pain and adjacencies. I'm proud of our team's continued focus and discipline, which are driving innovation, improving patient outcomes, and creating long-term value for our shareholders.”
earnings 2025-11-06
$25.9 million in-process R&D impairment recognized for ZILRETTA shoulder indication due to revised clinical trial completion timelines and reduced fair value estimate 26
$25.9 million in-process R&D impairment recognized for ZILRETTA shoulder indication due to revised clinical trial completion timelines and reduced fair value estimate 26
Guidance cut 2025-11-06
Full-year 2025 total revenue guidance narrowed to $725-735 million from prior guidance of $730-750 million 27
Full-year 2025 total revenue guidance narrowed to $725-735 million from prior guidance of $730-750 million 27
New market 2025-11-06
Entered exclusive worldwide license agreement with AmacaThera for PCRX-2002 (AMT-143), a long-acting ropivacaine formulation for postsurgical pain, with $5.0 million upfront payment and development and sales-based milestones 27
Entered exclusive worldwide license agreement with AmacaThera for PCRX-2002 (AMT-143), a long-acting ropivacaine formulation for postsurgical pain, with $5.0 million upfront payment and development and sales-based milestones 27
“Throughout the second quarter, we continued to make important progress advancing our 5x30 growth strategy to accelerate topline growth and fuel our transition into an innovative biopharmaceutical organization. We continue to focus on driving broad market adoption for EXPAREL. We are seeing encouraging momentum from leading indicators reinforcing our belief that EXPAREL is poised for sustainable growth and expanded market leadership.”
Margin expanding 2025-08-05
Non-GAAP gross margin improved to 82% in Q2 2025 from 76% in Q2 2024, driven by transition to large-scale manufacturing efficiencies and lower EXPAREL inventory reserves 25
Non-GAAP gross margin improved to 82% in Q2 2025 from 76% in Q2 2024, driven by transition to large-scale manufacturing efficiencies and lower EXPAREL inventory reserves 25
Guidance raised 2025-08-05
Full-year 2025 non-GAAP gross margin guidance raised to 78-80% from prior guidance of 76-78%, reflecting manufacturing efficiency gains 25
Full-year 2025 non-GAAP gross margin guidance raised to 78-80% from prior guidance of 76-78%, reflecting manufacturing efficiency gains 25
Strategic pivot 2025-08-05
Entered strategic co-promotion collaboration with Johnson & Johnson MedTech to expand ZILRETTA market reach to existing and new customers in the U.S. 24
Entered strategic co-promotion collaboration with Johnson & Johnson MedTech to expand ZILRETTA market reach to existing and new customers in the U.S. 24
Operating income halved 2025-08-05
Operating income more than halved YoY (28.2 to USD 8.5 million, -70%). 125
Operating income more than halved YoY (28.2 to USD 8.5 million, -70%). 125
“Our confidence in Pacira's future remains steadfast and the recently announced $300 million stock buyback program underscores our belief in our team, products, and long-term growth outlook.”
Margin expanding 2025-05-08
U.S. District Court ruled that royalties previously paid to Research Development Foundation on EXPAREL are no longer owed, eliminating low single-digit royalty payments and improving gross margin going forward 22
U.S. District Court ruled that royalties previously paid to Research Development Foundation on EXPAREL are no longer owed, eliminating low single-digit royalty payments and improving gross margin going forward 22
Strategic pivot 2025-05-08
Settled EXPAREL patent infringement suits with Fresenius Kabi USA, eVenus Pharmaceuticals, and Jiangsu Hengrui Pharmaceuticals; volume-limited generic bupivacaine liposome entry permitted beginning early 2030, with unlimited generic entry from 2039 22
Settled EXPAREL patent infringement suits with Fresenius Kabi USA, eVenus Pharmaceuticals, and Jiangsu Hengrui Pharmaceuticals; volume-limited generic bupivacaine liposome entry permitted beginning early 2030, with unlimited generic entry from 2039 22
Acquisition 2025-05-08
Acquired remaining 81% equity interest in GQ Bio Therapeutics GmbH for $30.3 million, consolidating the HCAd high-capacity adenovirus gene therapy vector platform and the PCRX-201 pipeline 22
Acquired remaining 81% equity interest in GQ Bio Therapeutics GmbH for $30.3 million, consolidating the HCAd high-capacity adenovirus gene therapy vector platform and the PCRX-201 pipeline 22
Operating income halved 2025-05-08
Operating income more than halved YoY (13.2 to USD 2.0 million, -85%). 22
Operating income more than halved YoY (13.2 to USD 2.0 million, -85%). 22
2024 · 16 events
“Pacira enters 2025 with a sharp focus on executing our 5x30 strategy to accelerate our transition into an innovative biopharmaceutical organization and therapeutic area leader in musculoskeletal pain and adjacencies. The new year is off to a strong start, highlighted by the recent implementation of NOPAIN, which we believe will drive greater utilization of EXPAREL and iovera° by significantly expanding patient access in outpatient settings. We are confident in our ability to drive growth in our base business and advance a novel pipeline of potentially transformative assets, like PCRX-201.”
“We enter 2025 with a sharp focus on growth, operational excellence and a clear mission to deliver innovative, non-opioid pain therapies to transform the lives of patients. Looking ahead, I am energized to lead Pacira during this exciting new chapter as we advance our 5x30 plan to address unmet patient needs in musculoskeletal pain and adjacencies. With a best-in-class commercial portfolio that is producing significant cash flow, we believe we are well equipped to extend our leadership in non-opioid pain management and transform Pacira into an innovative biopharmaceutical organization with a robust pipeline to support sustainable growth and enhanced value creation.”
Margin expanding 2025-02-27
Full-year gross margin improved to 76% from 73% in 2023; full-year adjusted EBITDA increased 4% to $223.9 million from $214.5 million in 2023 21
Full-year gross margin improved to 76% from 73% in 2023; full-year adjusted EBITDA increased 4% to $223.9 million from $214.5 million in 2023 21
revenue 2025-01-10
Full-year 2024 revenues reached $701.0 million, up 4% from $675.0 million in 2023; EXPAREL $549.0 million, ZILRETTA $118.1 million, iovera° $22.8 million, with average daily EXPAREL volume growth of 4% 19
Full-year 2024 revenues reached $701.0 million, up 4% from $675.0 million in 2023; EXPAREL $549.0 million, ZILRETTA $118.1 million, iovera° $22.8 million, with average daily EXPAREL volume growth of 4% 19
Strategic pivot 2025-01-10
Announced five-year 5x30 strategic plan targeting more than three million patients treated per year, double-digit revenue CAGR, five percentage point gross margin improvement, five novel pipeline programs, and five partnerships by 2030 19
Announced five-year 5x30 strategic plan targeting more than three million patients treated per year, double-digit revenue CAGR, five percentage point gross margin improvement, five novel pipeline programs, and five partnerships by 2030 19
“The work we have completed this year positions us to enter 2025 from a new place of focus, commitment, and strategic strength. We are confident the investments we are making will support and expand our leadership in non-opioid pain management and ensure we are positioned for sustainable success.”
Net income turned negative 2024-11-06
GAAP net loss of $143.5 million in Q3 2024 including $163.2 million goodwill impairment; impairment triggered by FDA approval of generic EXPAREL competitor in July 2024 and U.S. District Court patent invalidity ruling in August 2024 18
GAAP net loss of $143.5 million in Q3 2024 including $163.2 million goodwill impairment; impairment triggered by FDA approval of generic EXPAREL competitor in July 2024 and U.S. District Court patent invalidity ruling in August 2024 18
Strategic pivot 2024-11-06
FDA approved generic competitor to EXPAREL in July 2024; U.S. District Court ruled EXPAREL U.S. Patent No. 11,033,495 invalid on grounds of obviousness and anticipation in August 2024; notice of appeal filed September 2024 17
FDA approved generic competitor to EXPAREL in July 2024; U.S. District Court ruled EXPAREL U.S. Patent No. 11,033,495 invalid on grounds of obviousness and anticipation in August 2024; notice of appeal filed September 2024 17
New market 2024-11-06
CMS confirmed EXPAREL and iovera° qualify as eligible non-opioid products under NOPAIN Act with separate Medicare reimbursement beginning January 1, 2025; permanent J-code (J0666) established for EXPAREL 18
CMS confirmed EXPAREL and iovera° qualify as eligible non-opioid products under NOPAIN Act with separate Medicare reimbursement beginning January 1, 2025; permanent J-code (J0666) established for EXPAREL 18
Net cash to net debt 2024-11-06
Net debt position flipped (-137.3 to +USD 62.5 million vs 2024-Q2). 118
Net debt position flipped (-137.3 to +USD 62.5 million vs 2024-Q2). 118
“Looking ahead to the back half of the year, we remain sharply focused on preparations to maximize the benefit of separate EXPAREL reimbursement for outpatient procedures with the implementation of NOPAIN in January 2025.”
Revenue accelerating 2024-07-30
Total revenues increased to $178.0 million from $169.5 million in Q2 2023; iovera° net product sales grew 29% to $5.7 million driven by Smart Tip volume 16
Total revenues increased to $178.0 million from $169.5 million in Q2 2023; iovera° net product sales grew 29% to $5.7 million driven by Smart Tip volume 16
Margin expanding 2024-07-30
Gross margin expanded 3 percentage points in Q2 2024 versus Q2 2023, primarily due to lower EXPAREL product cost and lower royalty expense following August 2023 court ruling 15
Gross margin expanded 3 percentage points in Q2 2024 versus Q2 2023, primarily due to lower EXPAREL product cost and lower royalty expense following August 2023 court ruling 15
New market 2024-07-30
CMS proposed separate Medicare reimbursement for EXPAREL at ASP plus 6% in ambulatory surgical center and hospital outpatient settings under NOPAIN Act, effective January 1, 2025 15
CMS proposed separate Medicare reimbursement for EXPAREL at ASP plus 6% in ambulatory surgical center and hospital outpatient settings under NOPAIN Act, effective January 1, 2025 15
Net cash build 2024-07-30
Net cash position expanded to USD 137.3 million from USD 62.9 million in 2024-Q1 (+118%, derived from reported financial debt minus cash). 116
Net cash position expanded to USD 137.3 million from USD 62.9 million in 2024-Q1 (+118%, derived from reported financial debt minus cash). 116
“Our confidence in Pacira's future remains steadfast and the $150 million stock buyback announced today underscores our belief in our team, products, and growth outlook.”
earnings 2024-05-07
Q1 GAAP net income of $9.0 million versus net loss of $19.5 million in Q1 2023 14
Q1 GAAP net income of $9.0 million versus net loss of $19.5 million in Q1 2023 14
Strategic pivot 2024-05-07
Restructuring plan initiated in February 2024 to reshape executive team, reallocate resources from ex-U.S. and early-stage programs to U.S. commercial portfolio, and reprioritize investments for NOPAIN Act implementation 14
Restructuring plan initiated in February 2024 to reshape executive team, reallocate resources from ex-U.S. and early-stage programs to U.S. commercial portfolio, and reprioritize investments for NOPAIN Act implementation 14
New market 2024-05-07
PCRX-201 granted FDA Regenerative Medicine Advanced Therapy designation in March 2024, first gene therapy candidate for osteoarthritis to receive RMAT designation 14
PCRX-201 granted FDA Regenerative Medicine Advanced Therapy designation in March 2024, first gene therapy candidate for osteoarthritis to receive RMAT designation 14
Net debt to net cash 2024-05-07
Net debt position flipped (+369.1 to -USD 62.9 million vs 2023-Q4). 13
Net debt position flipped (+369.1 to -USD 62.9 million vs 2023-Q4). 13
Cash flow inflection 2024-05-07
Operating cash flow reached USD 49.1 million vs USD 19.1 million in 2023-Q1 (×2.6). 13
Operating cash flow reached USD 49.1 million vs USD 19.1 million in 2023-Q1 (×2.6). 13
2023 · 12 events
“Now that I have spent several weeks working with the Pacira team, I am even more enthusiastic to lead this great company as we build upon an impressive foundation of success. Looking ahead, we are sharply focused on driving long-term growth, furthering our patient centric culture and establishing high standards for operational excellence. Throughout 2024, we plan to advance the launch of EXPAREL in two key lower extremity nerve blocks and prepare for the significant catalyst ahead in NOPAIN. In parallel, we are taking the necessary steps to reallocate our efforts and resources to ensure the organization is best positioned for sustainable success. We have the people, the purpose, and the products to change the course of pain management and, hopefully, to help save patients from the deadly effects of opioid addiction.”
Strategic pivot 2024-02-29
Frank D. Lee succeeded David Stack as Chief Executive Officer effective January 2, 2024, completing the CEO transition initiated with Stack's retirement announcement in Q3 2023 11
Frank D. Lee succeeded David Stack as Chief Executive Officer effective January 2, 2024, completing the CEO transition initiated with Stack's retirement announcement in Q3 2023 11
New market 2024-02-29
FDA approved sNDA expanding EXPAREL label to include adductor canal block and sciatic nerve block in the popliteal fossa in adults, based on two Phase 3 studies showing statistically significant reductions in cumulative pain scores and opioid consumption 11
FDA approved sNDA expanding EXPAREL label to include adductor canal block and sciatic nerve block in the popliteal fossa in adults, based on two Phase 3 studies showing statistically significant reductions in cumulative pain scores and opioid consumption 11
“Pacira continues to operate from a position of financial strength with substantial revenues, improving gross margins, and ongoing operating discipline, which have resulted in significantly positive adjusted EBITDA of $53 million for the third quarter. Our strong and durable cash flows, fueled by EXPAREL exclusivity through 2041, leave us well positioned to self-fund our growth and deliver multiple value-creating milestones in the coming year including the anticipated launch of EXPAREL in two key lower extremity nerve blocks. Looking ahead, we will continue to actively manage operating expenses while deploying capital in a manner we believe will maximize shareholder return and unlock the significant untapped potential within our best-in-class opioid-sparing commercial portfolio.”
earnings 2023-11-02
Q3 2023 GAAP net income of $10.9 million ($0.23 per share) compared to a net loss of $0.7 million ($0.02 per share) in Q3 2022 9
Q3 2023 GAAP net income of $10.9 million ($0.23 per share) compared to a net loss of $0.7 million ($0.02 per share) in Q3 2022 9
Guidance cut 2023-11-02
Full-year EXPAREL guidance cut a second time to $535-540 million from $550-560 million, reflecting continued 340B pricing headwinds on net selling price 9
Full-year EXPAREL guidance cut a second time to $535-540 million from $550-560 million, reflecting continued 340B pricing headwinds on net selling price 9
Strategic pivot 2023-11-02
CEO David Stack announced intention to retire upon appointment of a successor; four new independent directors appointed to the Board in October 2023 9
CEO David Stack announced intention to retire upon appointment of a successor; four new independent directors appointed to the Board in October 2023 9
“We were pleased to see EXPAREL year-over-year growth rates improve as the quarter progressed, with a meaningful uptick in June. Solid year-over-year growth continued in July, leaving us optimistic for a stronger second half of the year given improving market conditions and rising demand for joint replacements and other elective surgeries. We also expect to benefit from several ongoing growth initiatives in the second half of 2023, such as continued volume expansion for existing and new 340B customers, as well as new initiatives with oral and maxillofacial surgeons, Plastics, Outpatient, and Sports Management.”
Revenue decelerating 2023-08-02
EXPAREL net product sales declined 1% to $135.1 million in Q2 2023, as 4% volume growth was more than offset by lower net selling price from 340B Drug Pricing Program implementation 6
EXPAREL net product sales declined 1% to $135.1 million in Q2 2023, as 4% volume growth was more than offset by lower net selling price from 340B Drug Pricing Program implementation 6
Guidance cut 2023-08-02
Full-year EXPAREL guidance lowered to $550-560 million from $570-580 million; ZILRETTA guidance reduced to $110-115 million from $115-125 million; non-GAAP gross margin guidance revised to 73%-74% from 76%-78% 7
Full-year EXPAREL guidance lowered to $550-560 million from $570-580 million; ZILRETTA guidance reduced to $110-115 million from $115-125 million; non-GAAP gross margin guidance revised to 73%-74% from 76%-78% 7
Operating income turned positive 2023-08-02
Operating income turned positive for the first time after 2 negative periods (-3.1 to +USD 39.9 million). 107
Operating income turned positive for the first time after 2 negative periods (-3.1 to +USD 39.9 million). 107
Net income turned positive 2023-08-02
Net income turned positive for the first time after 3 negative periods (-19.5 to +USD 25.8 million). 107
Net income turned positive for the first time after 3 negative periods (-19.5 to +USD 25.8 million). 107
“2023 is off to a positive start as EXPAREL continues to outperform the elective surgery market with expanding utilization across key target markets and all sites of care. The rollout of our 340B pricing program has performed according to plan with volumes expanding within both existing and naïve business. For ZILRETTA and iovera°, our full field-based team is broadening awareness and we are seeing a significant increase in first-time customers for these complementary and standalone non-opioid solutions for managing osteoarthritis pain.”
earnings 2023-05-03
Q1 2023 GAAP net loss of $19.5 million ($0.43 per share) vs net income of $6.8 million in Q1 2022, reflecting higher SG&A investment and gross margin compression from EXPAREL inventory reserves and 340B discounting 5
Q1 2023 GAAP net loss of $19.5 million ($0.43 per share) vs net income of $6.8 million in Q1 2022, reflecting higher SG&A investment and gross margin compression from EXPAREL inventory reserves and 340B discounting 5
Margin compressing 2023-05-03
Gross margin fell 8 percentage points to 69% in Q1 2023 from 77% in Q1 2022, driven by EXPAREL inventory reserves, higher product costs, and increased 340B discounting 4
Gross margin fell 8 percentage points to 69% in Q1 2023 from 77% in Q1 2022, driven by EXPAREL inventory reserves, higher product costs, and increased 340B discounting 4
New market 2023-05-03
FDA accepted sNDA seeking EXPAREL label expansion for adductor canal block and sciatic nerve block in the popliteal fossa in adults, with PDUFA action date of November 13, 2023 5
FDA accepted sNDA seeking EXPAREL label expansion for adductor canal block and sciatic nerve block in the popliteal fossa in adults, with PDUFA action date of November 13, 2023 5
Pacira Biosciences Business Model
How Pacira Biosciences (PCRX) makes its money, summarised from the filings up to Q2 2026, neutral and without forecast. NadirAlpha methodology
Pacira BioSciences is a specialty pharmaceutical company focused on non-opioid pain management and regenerative medicine for patients in surgical, interventional, and musculoskeletal care settings. Revenue is generated primarily through the sale of two commercial products: EXPAREL (bupivacaine liposome injectable suspension), a long-acting postsurgical local analgesic administered across a broad range of surgical procedures and representing the largest share of net product sales; and ZILRETTA (triamcinolone acetonide extended-release injectable suspension), indicated for osteoarthritis knee pain and under Phase 3 evaluation for shoulder osteoarthritis. Products are sold to hospitals, ambulatory surgical centers, and specialty distributors, with commercial uptake dependent on payer reimbursement coverage and physician adoption. Following the July 2026 divestiture of the iovera° cryoanalgesia product line to Zimmer Biomet, the commercial portfolio is concentrated on EXPAREL and ZILRETTA. Pacira Biosciences also licenses EXPAREL for commercialization in select Asian-Pacific markets through LG Chem and is advancing PCRX-201, an HCAd-based gene therapy candidate for osteoarthritis, through Phase 2 clinical trials.
Pacira Biosciences Stock: Share-Price Drivers
What determines the business trajectory of Pacira Biosciences according to management, summarised from the reports up to Q2 2026. NadirAlpha methodology
EXPAREL commercial trajectory under expanding payer reimbursement and the approaching generic bupivacaine liposome entry
EXPAREL is Pacira's largest product and the main swing factor for group revenue of USD 192.4 million in 2026-Q2; UnitedHealthcare approved separate reimbursement for EXPAREL, while a generic bupivacaine liposome entry is anticipated around 2030 33 29
EXPAREL is Pacira's largest product and the main swing factor for group revenue of USD 192.4 million in 2026-Q2; UnitedHealthcare approved separate reimbursement for EXPAREL, while a generic bupivacaine liposome entry is anticipated around 2030 33 29
EXPAREL volume and reimbursement access
EXPAREL revenue was higher year on year, up 5.9% 27, and UnitedHealthcare approved separate reimbursement for EXPAREL in July 2026, supporting broader access 33
EXPAREL revenue was higher year on year, up 5.9% 27, and UnitedHealthcare approved separate reimbursement for EXPAREL in July 2026, supporting broader access 33
iovera° uptake and indication expansion
iovera° grew 14.3% 27 and Pacira is advancing it toward a spasticity indication with a pivotal trial underway, plus an FDA-cleared 25-gauge Smart Tip 20 33
iovera° grew 14.3% 27 and Pacira is advancing it toward a spasticity indication with a pivotal trial underway, plus an FDA-cleared 25-gauge Smart Tip 20 33
ZILRETTA franchise
ZILRETTA revenue was broadly stable to modestly higher, up 2.1% 27, with a Phase 3 shoulder osteoarthritis study whose enrollment completed in April 2026 33
ZILRETTA revenue was broadly stable to modestly higher, up 2.1% 27, with a Phase 3 shoulder osteoarthritis study whose enrollment completed in April 2026 33
PCRX-201 gene therapy pipeline in knee osteoarthritis
Pacira expects Phase 2 ASCEND Part A topline data by the end of 2026 and transitioned PCRX-201 to a U.S.-based commercial manufacturing process 33
Pacira expects Phase 2 ASCEND Part A topline data by the end of 2026 and transitioned PCRX-201 to a U.S.-based commercial manufacturing process 33
Generic bupivacaine liposome competition
A generic bupivacaine liposome entry is anticipated around 2030, a longer-term threat to EXPAREL exclusivity 29
A generic bupivacaine liposome entry is anticipated around 2030, a longer-term threat to EXPAREL exclusivity 29
International EXPAREL expansion via LG Chem
Pacira entered an LG Chem partnership for EXPAREL in Asian-Pacific markets, with marketing authorization filings planned in South Korea and Thailand 29 33
Pacira entered an LG Chem partnership for EXPAREL in Asian-Pacific markets, with marketing authorization filings planned in South Korea and Thailand 29 33
PCRX-2002 early-stage development
Pacira in-licensed PCRX-2002 from AmacaThera and expects to initiate a Phase 2 bunionectomy trial in September 2026 31 33
Pacira in-licensed PCRX-2002 from AmacaThera and expects to initiate a Phase 2 bunionectomy trial in September 2026 31 33
Sector trend: Demand for non-opioid acute and chronic pain therapies is being supported by reimbursement and policy tailwinds, including separate EXPAREL reimbursement from UnitedHealthcare and the NOPAIN framework 33 29. Group profitability improved against decelerating top-line growth, while management guidance was lowered.
Pacira Biosciences Revenue by Type (as of 2026-Q2 · USD million · 3/3)
Revenue of Pacira Biosciences split by segment or product type exactly as the company itself reports it; segment totals can deviate from group revenue. NadirAlpha methodology
| Segment | Since | Revenue | Growth | Source |
|---|---|---|---|---|
| Period 2025-Q3 (3M) | ||||
| ZILRETTA | 2022-Q4 | 29 | 2.1% | 27 |
| iovera° | 2022-Q4 | 6.5 | 14.3% | 27 |
| EXPAREL | 2022-Q4 | – | 5.9% | 27 |
Pacira Biosciences Products & announcements (28/69 active+recent)
Product announcements of Pacira Biosciences from the reports: market launches, approvals, partnerships, with first mention and source; discontinued products are shown in grey. NadirAlpha methodology
Status: PlannedLaunched
| Product/Line | Since | Status | Source |
|---|---|---|---|
| 2030 | |||
| Generic bupivacaine liposome entry | 2030 | 29 | |
| 2026 | |||
| PCRX-2002 Phase 2 bunionectomy trial expected to initiate | 2026-09 | 33 | |
| UnitedHealthcare separate reimbursement for EXPAREL approved | 2026-07 | 33 | |
| PCRX-201 manufacturing transitioned to U.S.-based commercial manufacturing process | 2026-07 | 33 | |
| PCRX-201 Phase 1 study publication in Annals of the Rheumatic Diseases | 2026 | 34 | |
| PCRX-2002 Phase 2 program initiation (2x) | 2026 | 29 | |
| LG Chem marketing authorization filings in South Korea and Thailand (2x) | 2026 | 29 | |
| AMT-143 Phase 2 program | 2026 | 26 | |
| 2025 | |||
| Patent infringement settlement with Fresenius Kabi, eVenus, and Jiangsu Hengrui | 2025-09 | 27 | |
| EXPAREL pediatric registration program | 2025-09 | 26 | |
| EXPAREL U.S. Patent No. 12,370,142 issuance | 2025-08 | 27 | |
| eVenus Paragraph IV settlement agreement | 2025-04 | 29 | |
| Settlement with eVenus ANDA Filers allowing generic bupivacaine liposome entry | 2025-04 | 29 | |
| Patent No. 12,251,468 for EXPAREL composition | 2025-03 | 23 | |
| iovera° New Medicare C-Code (C9809) Implementation | 2025-01 | 29 | |
| Laura Brege appointed Board Chair | 2025-01 | 21 | |
| Krys Corbett appointed Chief Business Officer | 2025-01 | 21 | |
| Jubilant Hollisterstier Manufacture and Supply Agreement | 2025-01 | 29 | |
| FDA clearance of 25-gauge 180mm Smart Tip for iovera° | 2025-01 | 20 | |
| EXPAREL separate Medicare reimbursement implementation (4×) | 2025-01 | 29 | |
| Brendan Teehan appointed Chief Commercial Officer | 2025-01 | 21 | |
| ZILRETTA shoulder indication clinical trial ongoing | 2025 | 29 | |
| EXPAREL pediatric trial Part 1 completion | 2025 | 24 | |
| 2024 | |||
| HCPCS J-code (J0666) for EXPAREL (4×) | 2024-10 | 29 | |
| iovera° spasticity pivotal trial (7×) | 2024-06 | 29 | |
| 2023 | |||
| PCRX-201 Phase 2 ASCEND trial (25×) | 2023-06 | 20 | |
| ZILRETTA shoulder OA Phase 3 trial (13×) | 2023-03 | 33 | |
| EXPAREL pediatric Phase 1 study launch (4×) | 2023-03 | 22 | |
| 2024 | |||
| iovera° medial branch block Smart Tip (8×) | 2024-12 | 31 | |
| iovera° SmartTip FDA 510(k) clearance | 2024-12 | 21 | |
| U.S. Patent No. 12,156,940 for EXPAREL manufacturing | 2024-12 | 21 | |
| Phase 1 data presentation for PCRX-201 in knee osteoarthritis | 2024-11 | 20 | |
| PCRX-201 gene therapy development (3×) | 2024-11 | 14 | |
| PCRX-201 2-year safety and efficacy data | 2024-11 | 21 | |
| New C-code (C9809) for iovera° Medicare reimbursement in ASC and HOPD settings | 2024-11 | 20 | |
| Issuance of $287.5 million 2.125% convertible senior notes due 2029 | 2024-05 | 20 | |
| U.S. Patent Nos. 11,918,565 and 11,931,459 for EXPAREL sciatic nerve block and pediatric use | 2024-03 | 20 | |
| EXPAREL patents issued (3 patents) | 2024-03 | 13 | |
| PCT application for ZILRETTA OA pain treatment in diabetic patients | 2024-02 | 20 | |
| PCRX-201 (2×) | 2024-02 | 29 | |
| Manufacturing suite approval at Science Center Campus San Diego (4×) | 2024-02 | 20 | |
| Enhanced Large-Scale Manufacturing Process for EXPAREL (San Diego) | 2024-02 | 29 | |
| 200-liter EXPAREL manufacturing suite | 2024-02 | 15 | |
| National group purchasing agreement with Premier for EXPAREL | 2024-01 | 11 | |
| iovera° expansion to spasticity indication | 2024 | 20 | |
| 2023 | |||
| NOPAIN catalyst | 2023-12 | 12 | |
| ZILRETTA capital project in Swindon, England | 2023-06 | 9 | |
| EXPAREL intrathecal analgesia Phase 1 study (3×) | 2023-06 | 15 | |
| EXPAREL capacity expansion sNDA submission | 2023-06 | 6 | |
| EXPAREL capacity expansion in San Diego, California (2×) | 2023-06 | 8 | |
| Distribution agreement with Eurofarma for EXPAREL in Latin America | 2023-06 | 6 | |
| Term Loan A refinancing, retirement of Term Loan B | 2023-03 | 4 | |
| TLA Credit Agreement refinancing | 2023-03 | 6 | |
| FDA sNDA acceptance for EXPAREL nerve blocks in lower extremity procedures | 2023-03 | 5 | |
| EXPAREL stellate ganglion block Phase 3 study (5×) | 2023-03 | 15 | |
| Houston Pacira Innovation and Training Center (3×) | 2023-01 | 8 | |
| 2022 | |||
| Brazil regulatory application for EXPAREL via Eurofarma distribution agreement | 2022-12 | 4 | |
| 2021 | |||
| eVenus ANDA amendment for generic EXPAREL 133 mg/10 mL | 2021-12 | 20 | |
| eVenus ANDA Paragraph IV certification for EXPAREL 266 mg/20 mL (3×) | 2021-10 | 20 | |
| Distribution agreement with Verve Medical Products for iovera° in Canada | 2021-07 | 6 | |
| EXPAREL pediatric sNDA approval for children aged 6-17 | 2021-03 | 20 | |
| EXPAREL approved for pediatric use in patients six years and older | 2021-03 | 20 | |
| EXPAREL approval for patients six years of age and older (2×) | 2021-03 | 20 | |
| EXPAREL FDA approval for pediatric patients ages 6-17 | 2021-03 | 29 | |
| 2020 | |||
| DOJ settlement resolving investigation of EXPAREL marketing and promotional practices | 2020-07 | 20 | |
| 2018 | |||
| EXPAREL lower extremity nerve block launch (21×) | 2018-04 | 14 | |
| 2012 | |||
| EXPAREL commercial launch | 2012-04 | 29 | |
| Undated | |||
| iovera° spasticity investigational device exemption study | planned | 20 | |
| EXPAREL pediatric indication under six years | planned | 20 | |
Pacira Biosciences Transactions & Events (20)
All recorded acquisitions, divestitures and exits of Pacira Biosciences, plus partnerships, contracts and regulatory events affecting the business, each with date and source. NadirAlpha methodology
Acquisitions · 3Partnerships/contracts · 7Divestitures/exits · 1Regulation/legislation · 3older: 6 (in the table)
Acquisitions by Pacira Biosciences
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2025 | |||
| GQ Bio Acquisition - exclusive license for HCAd gene therapy vector encoding PRG4 | 2025-02 | Completed | 20 |
| GQ Bio Acquisition (5×) | 2025-02 | Completed | 32 |
| PCRX-2002 In-Licensing from AmacaThera | 2025 | Completed | 30 |
| 2021 | |||
| Flexion Acquisition (3×) | 2021-11 | Completed | 29 |
| 2019 | |||
| MyoScience Acquisition (2×) | 2019-04 | Completed | 29 |
| 2011 | |||
| EXPAREL EC approval (7×) | 2011-10 | Completed | 29 |
| 2007 | |||
| Pacira Pharmaceuticals acquisition from SkyePharma | 2007-03 | Completed | 20 |
Divestitures and exits by Pacira Biosciences
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| iovera° divestiture to Zimmer Biomet | 2026-07 | Divested | 34 |
Partnerships and contracts of Pacira Biosciences
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| LG Chem partnership for EXPAREL in Asia-Pacific markets (2x) | 2026-01 | Agreement | 29 |
| LG Chem EXPAREL Partnership Agreement (2x) | 2026-01 | Agreement | 29 |
| 2025 | |||
| New group purchasing organization (GPO) partnership | 2025-12 | Agreement | 28 |
| AMT-143 exclusive license agreement with AmacaThera | 2025-11 | Agreement | 27 |
| Co-promotion agreement with J&J MedTech for ZILRETTA (3x) | 2025-07 | Agreement | 29 |
| AmacaThera license agreement (3x) | 2025 | Agreement | 31 |
| 2023 | |||
| Partnership with PGA TOUR Champions for iovera° sponsorship | 2023-04 | Agreement | 5 |
| 2021 | |||
| Termination of DePuy Synthes co-promotion agreement for EXPAREL | 2021-01 | Agreement | 20 |
Regulation and legislation at Pacira Biosciences
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2025 | |||
| NOPAIN Act implementation - separate EXPAREL reimbursement in outpatient surgical environments | 2025-01 | Regulation | 16 |
| NOPAIN for Veterans Act (H.R. 5409 / S. 3209) | 2025 | Regulation | 29 |
| NOPAIN Act rollout (3×) | 2025 | Regulation | 29 |
Terminated or withdrawn
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2021 | |||
| Flexion Acquisition completing ZILRETTA addition to product portfolio | 2021-11 | Terminated (2023-01) | 29 |
Pacira Biosciences Risks (170 since the annual report of 2026-02-26, 361 tracked in total)
Risk factors Pacira Biosciences itself names in its reports, merged by topic across periods, with category, first mention and source; new risks of the latest period come first. NadirAlpha methodology
Category: LegalRegulatoryCompetitionFinancialCustomersStrategyTechnologyMacroSupply chainMarketESGPeopleCyberGeopolitics
| Risk | Category | Last reported |
|---|---|---|
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2026-08-04 (2026-Q2), source 34 | ||
| Risks associated with successful integration of divested iovera° business and realization of anticipated benefits. | = | |
| Timing and success of FDA supplemental New Drug Applications and European Medicines Agency Marketing Authorization Applications. | = | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2026-08-04 (2026-Q2), source 33 | ||
| Two Chinese generic manufacturers filed ANDA applications for generic EXPAREL; company engaged in patent infringement litigation to defend intellectual property. | = | |
| Global economic conditions, inflation, and tariffs expected to increase manufacturing, raw materials, equipment and labor costs, negatively impacting gross margins and cash flow. | = | |
| Expansion of EXPAREL reimbursement requires continued payer negotiations and adoption; reimbursement changes could materially impact revenue growth and market access. | = | |
| Divestiture may not achieve anticipated strategic, operational or financial objectives; potential failure to realize expected benefits or receive milestone payments could materially adversely affect business. | = | |
| Revenue-based milestone payments of up to $70.0 million through 2031 contingent on Zimmer's commercialization efforts and market performance, with no assurance of achievement. | = | |
| Company facing patent infringement litigation related to MyoScience acquisition; costs and outcomes unpredictable and could materially impact financial condition. | = | |
| Required compliance with FDA regulations for additional pediatric trials on EXPAREL as condition of approval; timing and outcomes of trials uncertain. | = | |
| Success dependent on rate and degree of EXPAREL market acceptance and ability to expand to additional indications; timing and success of clinical trials uncertain. | = | |
| PCRX-201 development risk includes successful completion of Phase 2 ASCEND trial, regulatory approval and commercialization; manufacturing process recently transitioned requiring validation. | = | |
| ZILRETTA shoulder OA indication depends on Phase 3 trial success; approval not assured and expansion to additional indications contingent on regulatory approval. | = | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2026-01-08 (2025-Q4), source 28 | ||
| Strength and efficacy of intellectual property protection and patent terms for product portfolio. | 2026-Q2 2026-08-04 34 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2025-11-06 (2025-Q3), source 27 | ||
| Success of clinical trials for PCRX-201 and other HCAd platform-based product candidates. | 2026-Q2 2026-08-04 34 | |
| Pacira Biosciences: first mention in 10-K annual report of 2025-02-27 (FY2024), source 20 | ||
| Timing and extent of 2029 Convertible Notes conversion by holders creates accounting and financing uncertainty; settlement terms allow for combination of cash and stock at company's option. | 2026-Q2 2026-08-04 33 | |
| U.S. tariffs of 10-15% on pharmaceutical products and APIs from primary suppliers in EU, UK, Japan, South Korea, Switzerland; magnitude and duration of impact uncertain. | 2026-Q2 2026-08-04 33 | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2024-05-07 (2024-Q1), source 13 | ||
| Prolonged inflation, tariffs, rising interest rates and economic uncertainty could adversely impact business, revenues, cash flows and results of operations. | 2026-Q2 2026-08-04 33 | |
| Pacira Biosciences: first mention in 10-K annual report of 2024-02-29 (FY2023), source 11 | ||
| Reliance on UK contract manufacturer and EU/Swiss API suppliers; tariffs, inflation and supply chain disruptions may cause longer lead-times and insufficient material procurement. | 2026-Q2 2026-08-04 33 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2024-01-04 (FY2023), source 10 | ||
| Potential contingent consideration payments to former Flexion shareholders could reach $372.3 million if certain regulatory and commercial milestones achieved, creating capital requirements uncertainty. | 2026-Q2 2026-08-04 33 | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2023-08-02 (2023-Q2), source 6 | ||
| $287.5 million in 2029 Convertible Notes maturing May 2029 and $81.0 million Revolving Credit Facility borrowings at 6.72% all-in rate create refinancing and interest rate risks. | 2026-Q2 2026-08-04 33 | |
| Interest rate increases would increase interest expense on variable-rate Revolving Credit Facility borrowings; 100 basis point increase would increase expense approximately $0.8 million annually. | 2026-Q2 2026-08-04 33 | |
| Risks associated with manufacturing and supply chain, including impact of global economic conditions and tariffs. | 2026-Q2 2026-08-04 34 | |
| Global and United States economic conditions including inflation and rising interest rates impact on business and financial performance. | 2026-Q2 2026-08-04 34 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2023-05-03 (2023-Q1), source 5 | ||
| Rate and degree of market acceptance of EXPAREL and ZILRETTA products. | 2026-Q2 2026-08-04 34 | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2023-05-03 (2023-Q1), source 4 | ||
| Accounts receivable concentrated with three large pharmaceutical wholesalers; non-performance or non-payment could materially adversely impact financial condition and cash flow. | 2026-Q2 2026-08-04 33 | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2026-04-30 (2026-Q1), source 31 | ||
| Potential milestone payments to former Flexion Therapeutics stockholders up to $372.3 million if regulatory and commercial milestones achieved by December 31, 2030. | = | |
| U.S. Presidential Order April 2026 imposes 15% tariffs on EU/Japan/Korea/Switzerland/Liechtenstein and 10% on U.K. pharmaceutical products; EXPAREL and ZILRETTA APIs and products affected. | = | |
| Two Chinese manufacturers filed ANDA Paragraph IV Certifications for generic EXPAREL; patent infringement suits filed November 2025. | = | |
| FDA requires additional pediatric trials for EXPAREL and EMA requires pediatric trials as conditions of approval; development costs and timing uncertain. | = | |
| ZILRETTA and EXPAREL manufactured by U.K. contract manufacturer; APIs sourced primarily from Europe; subject to supply disruption and tariff risks. | = | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2026-02-26 (FY2025), source 30 | ||
| Rate and degree of market acceptance and growth of EXPAREL dependent on continued adoption and reimbursement. | = | |
| Pacira Biosciences: first mention in 10-K annual report of 2026-02-26 (FY2025), source 29 | ||
| Success of PCRX-201, PCRX-2002 and other clinical programs depends on completing trials successfully; many clinical programs in early stages with uncertain outcomes. | 2026-Q1 2026-04-30 31 | |
| Subject to activist campaigns; past activism caused management distraction, expenses; stock price/strategy volatility | = | |
| Accumulated deficit of $199.3 million as of December 31, 2025; history of net losses 2016-2019 and 2024 | = | |
| Goodwill and intangible assets may face further impairment; $25.9 million ZILRETTA impairment in 2025; $163.2 million goodwill impairment in 2024 | = | |
| $378.5 million total gross indebtedness; significant interest and principal obligations; refinancing risk for 2029 Notes and Revolving Credit Facility | = | |
| Significant up-front fixed costs for manufacturing capacity expansion; demand/supply mismatch risk if market demand does not align with expanded capacity. | = | |
| Aratana can receive up to $40.0 million upon achievement of commercial milestones for NOCITA animal health product. | = | |
| Profitable only 2015, 2023, 2025; losses 2016-2019, 2024; future profitability uncertain | = | |
| Substantial R&D investments with uncertain outcomes; unsuccessful R&D could cause cost structure misalignment with demand. | = | |
| Dependence on adequate third-party payer coverage and reimbursement for EXPAREL and ZILRETTA at acceptable pricing levels. | = | |
| ZILRETTA market acceptance limited to single indication (OA knee pain); competes with inexpensive generic immediate-release steroids and HA-containing products. | = | |
| EXPAREL distribution requires cold-chain maintenance between specified temperatures; failure risks product adulteration; limited insurance coverage. | = | |
| Jubilant supplying ZILRETTA diluent under January 2025 agreement with three-year initial term and mutual extension consent requirement. | = | |
| Three wholesalers (McKesson 31%, Cardinal 26%, AmerisourceBergen 22%) account for 79% of total revenues; drop-ship program eliminates physical possession. | = | |
| Reliance on third-party distributors for product promotion and sales; distributors may not effectively market products, comply with regulations, or may reduce sales efforts. | = | |
| Dependence on third-party service providers for manufacturing, warehousing, distribution, customer service; failure to comply with regulations or meet deadlines could impair product delivery. | = | |
| San Diego, Swindon U.K., Amphenol Tijuana, and Jubilant Spokane manufacturing facilities subject to natural/man-made disaster risks (earthquakes, floods, fires); limited property and business interruption insurance. | = | |
| Intense competition for skilled personnel in San Francisco Bay Area, San Diego, northern New Jersey/New York metro, and Luckenwalde Germany; difficulty retaining key management and scientific staff. | = | |
| Aug 2024 ruling: EXPAREL patent 495 claim 7 invalid (obviousness/anticipation); appeal pending Sep 2024 | = | |
| Product side effects could result in labeling restrictions, distribution limitations, or market withdrawal | = | |
| July 2020 settlement with DOJ and State AGs regarding EXPAREL marketing; $3.5 million global settlement paid | = | |
| FDA oversight of EXPAREL/ZILRETTA/iovera safety; FDAAA expanded authority; post-approval studies/labeling changes may limit indications | = | |
| Future reimbursement policies may change unfavorably despite current NOPAIN Act and J-code provisions; no assurance of adequate reimbursement levels. | = | |
| Settlement with eVenus allows generic bupivacaine liposome entry beginning early 2030 at high single-digit percentages, increasing to low thirties by 2033. | = | |
| FDA-approved generic bupivacaine alternative exists; competitors developing cryogenic/alternative formulation products | = | |
| Risks related to cybersecurity threats, data privacy laws and failure to maintain information security. | = | |
| Attacks on IT systems, third-party vendors increasing in number/sophistication; breach risks confidentiality, operations, reputation damage | = | |
| Company subject to evolving privacy and data protection laws including GDPR and CCPA; non-compliance could result in substantial regulatory penalties and significant legal liability | = | |
| GDPR (4% worldwide revenue penalty), CCPA/CPRA compliance costs increasing; global privacy laws divergent | = | |
| ERP implementation/maintenance requires significant resources; system failures could disrupt operations, financial reporting | = | |
| Climate change and extreme weather could disrupt manufacturing sites and supply chain operations | = | |
| Failure to meet CSR expectations and standards could damage reputation and affect customer relationships | = | |
| Pandemic or infectious disease outbreak could cause material adverse effects on operations and cash flows | = | |
| Cash generation must service debt; refinancing risk if operating performance declines | = | |
| May require additional debt or equity financing; capital markets disruptions could limit access | = | |
| Ukraine/Israel-Hamas wars impact macroeconomic conditions, supply chains, operations; geopolitical instability ongoing | = | |
| Subject to varying reimbursement systems and price ceilings across international markets. | = | |
| Changes in U.S. and international trade policy could materially impact financial condition | = | |
| Quarterly operating results fluctuate with hospital/ASC demand levels and buying patterns | = | |
| Operating results subject to hospital/ASC demand fluctuations, payer policies, regulatory developments, geopolitical events | = | |
| Product success depends on Medicare, Medicaid and commercial payer coverage decisions and reimbursement rates. | = | |
| ZILRETTA competes with generic steroids and HA products; limited to OA knee pain indication | = | |
| Alternative sources available for most raw materials and components, but switching to alternatives could cause manufacturing delays. | = | |
| Single sources of supply for certain materials; supply disruptions could delay manufacturing | = | |
| Active pharmaceutical ingredients for EXPAREL and ZILRETTA sourced outside U.S.; subject to tariff risks; Supreme Court ruled against country-specific tariffs in February 2026 and 10% blanket tariff exempts pharmaceuticals | = | |
| Tariffs on imported active pharmaceutical ingredients and raw materials could increase costs | = | |
| Macroeconomic conditions (recessions, inflation, rates, credit tightening) impact demand/operations; government shutdowns affect FDA/CMS | = | |
| International operations expose company to foreign currency exchange rate fluctuations relative to U.S. dollar; changes in rates could adversely affect financial results | = | |
| U.S. Congress and state legislatures continue proposing cost containment initiatives affecting pharmaceutical pricing. | = | |
| Global inflation and tariffs increase freight costs and raw material expenses; may continue impacting results | = | |
| Economic slowdowns, recessions, inflation, rising interest rates, geopolitical conflicts impact business | = | |
| Rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera° may not meet expectations | = | |
| Subject to antitrust and competition regulations in jurisdictions where company operates; violations could result in significant fines and enforcement actions | = | |
| Risk of claims regarding former employees' alleged unauthorized use or disclosure of trade secrets | = | |
| Subject to federal and state anti-kickback and false claims laws; enforcement emphasis on pharmaceutical industry. | = | |
| Patent litigation complex, expensive, time-consuming; trade secrets difficult to protect globally | = | |
| Clinical trials expensive, time-consuming, outcomes uncertain; failure to complete could delay regulatory approval | = | |
| Subject to federal and state anti-kickback and false claims laws; increased enforcement attention in pharmaceutical and medical device industries. | = | |
| Affordable Care Act imposes drug rebates, 340B Drug Pricing Program participation, and pricing constraints; additional congressional healthcare changes possible. | = | |
| Subject to HIPAA, HITECH, and privacy/security regulations; potential civil and criminal penalties for non-compliance by covered entities and business associates. | = | |
| International operations expose company to numerous conflicting legal and regulatory requirements on pharmaceutical marketing, data protection, taxation, employment laws and anti-corruption compliance | = | |
| Six-month pediatric exclusivity available under Section 505A FDCA, adding to existing patent/non-patent exclusivity periods. | = | |
| NOPAIN Act effective January 1, 2025 mandates Medicare reimbursement for non-opioid products and devices in ASC/HOPD settings; NOPAIN for Veterans Act proposed to expand coverage. | = | |
| Third-party payer coverage and reimbursement availability uncertain; government programs may limit pricing and reimbursement rates. | = | |
| EMA and MHRA require REMS for EXPAREL while FDA does not; international regulatory requirements may limit pricing and distribution flexibility. | = | |
| Reliance on third-party distributors; failure to perform could reduce sales and incur additional costs | = | |
| Subject to customs laws and regulations for export and import activity; failure to comply could result in substantial fines and penalties discovered during government customs audits | = | |
| Clinical trials for PCRX-201 and other candidates may fail or be delayed, preventing regulatory approvals. | = | |
| Adoption and integration of AI tools presents risks including security threats to confidential information and potential regulatory investigations; unauthorized AI use by employees could expose sensitive data | = | |
| Competitors may develop alternative bupivacaine/TCA formulations, cryotherapy devices outside patent scope | = | |
| EXPAREL competes with generic bupivacaine, opioids (morphine, fentanyl, meperidine, hydromorphone), NSAIDs, and elastomeric pumps; generic entry may begin 2030 under settlement. | = | |
| iovera° competes with cooled radio-frequency ablation devices and other cryotherapy pain management competitors. | = | |
| Generic competition, alternative delivery systems, new entrants threaten EXPAREL/ZILRETTA/iovera market share | = | |
| Stock price volatile with trading range from $6.16 to $121.95 per share since 2011; fluctuations driven by commercial success of products, clinical trial results, competitive products, regulatory changes and broader market conditions | = | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2026-01-08 (2025-Q4), source 28 | ||
| Market acceptance rate for EXPAREL, ZILRETTA, and iovera° may not meet expectations | = | |
| Tariffs and inflation impact on manufacturing costs and revenues | = | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2025-11-06 (2025-Q3), source 27 | ||
| Court judgment requiring Research Development Foundation royalty repayment of $23.1 million; statutory interest adds $5.2 million obligation. | = | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2025-11-06 (2025-Q3), source 26 | ||
| Active ingredient bupivacaine patent protection expired; competitors can market alternative delivery formulations outside scope of pMVL patents if FDA-approved. | = | |
| FDA furloughs and scaled-back operations during shutdowns could delay regulatory reviews | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2025-05-08 (2025-Q1), source 22 | ||
| Up to $372.3 million potential contingent payments for Flexion Acquisition milestones through 2030 | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2025-02-27 (2024-Q4), source 21 | ||
| Significant competition from other pharmaceutical, medical device and biotechnology companies | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 10-K annual report of 2025-02-27 (FY2024), source 20 | ||
| Cybersecurity risks despite controls; no known material breaches in past three years, but potential for future attacks and data breaches. | FY2025 2026-02-26 29 | |
| Accumulated deficit $199.3M as of Dec 31, 2025; net income $7.0M in 2025, loss $99.6M in 2024 | FY2025 2026-02-26 29 | |
| Flexion Acquisition contingent value rights could aggregate up to $372.3 million if certain regulatory and commercial milestones are met. | FY2025 2026-02-26 29 | |
| Must maintain compliance with financial covenants under $300.0 million Revolving Credit Facility | FY2025 2026-02-26 29 | |
| May need to raise capital to fund product development and cannot guarantee sufficient cash flow from operations. | FY2025 2026-02-26 29 | |
| Federal and state NOL carryforwards may expire and not be used; use of certain NOLs limited under IRC Section 382 due to cumulative ownership changes exceeding 50% within three-year period | FY2025 2026-02-26 29 | |
| Emphasis on managed care increasing pressure on pharmaceutical and medical device pricing; potential for unfavorable future reimbursement rates. | FY2025 2026-02-26 29 | |
| Co-production agreements with Thermo Fisher involve regulatory approval requirements; failure to maintain approvals could have material adverse effect on operations. | FY2025 2026-02-26 29 | |
| Company faces increasing cybersecurity threats including social engineering, denial of service attacks and malware; potential breach could result in loss of revenues, misuse of confidential data and business disruption | FY2025 2026-02-26 29 | |
| May need additional funding; inability to raise capital could force delays or elimination of programs | FY2025 2026-02-26 29 | |
| Medicaid rebate changes may increase 340B discounts; third-party payer coverage/reimbursement restrictions expanding | FY2025 2026-02-26 29 | |
| Changes in reimbursement policies by government and private payers could adversely affect demand and pricing for company's products | FY2025 2026-02-26 29 | |
| Company dependent on key scientific and management personnel; loss of critical personnel could adversely impact business strategy execution and operations | FY2025 2026-02-26 29 | |
| Compliance with regulations and potential changes in regulatory landscape affecting product approvals and commercialization. | FY2025 2026-02-26 30 | |
| PCRX-201 and other product candidates depend on regulatory approval timelines | 2025-Q4 2026-01-08 28 | |
| Failure to comply with extensive healthcare regulatory requirements could result in fines and sanctions | FY2025 2026-02-26 29 | |
| Introduction of competitive products or technologies could negatively affect commercial success of EXPAREL, ZILRETTA and iovera°; generic competition for EXPAREL expected | FY2025 2026-02-26 29 | |
| ZILRETTA competes with immediate-release steroids, hyaluronic acid injections, and stem cell/PRP therapies in osteoarthritis market. | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2025-01-10 (2024-Q4), source 19 | ||
| Manufacturing and supply chain risks including tariffs, inflation and rising interest rates affecting revenues and cash flows. | FY2025 2026-02-26 30 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2024-11-06 (2024-Q3), source 18 | ||
| $163.2M goodwill impairment Q3 2024; $25.9M intangible asset impairment 2025 (ZILRETTA shoulder OA); carrying value $368.1M remains at risk | FY2025 2026-02-26 29 | |
| August 2024 court ruling invalidated EXPAREL patent | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2024-11-06 (2024-Q3), source 17 | ||
| In October 2025, received two Paragraph IV Certifications from Chinese generic manufacturers WhiteOak and Qilu for EXPAREL ANDA; filed patent infringement suit in November 2025 to defend intellectual property | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2024-07-30 (2024-Q2), source 16 | ||
| Manufacturing and supply chain challenges could impact commercialization | 2025-Q4 2026-01-08 28 | |
| Intense competition from well-established pharmaceutical, medical device and biotechnology companies with greater financial resources and R&D capabilities. | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2024-02-29 (2023-Q4), source 12 | ||
| GQ Bio acquisition integration success and realization of synergies uncertain | 2025-Q1 2025-05-08 22 | |
| Pacira Biosciences: first mention in 10-K annual report of 2024-02-29 (FY2023), source 11 | ||
| Risks associated with patent infringement litigation and settlement costs impacting financial performance. | FY2025 2026-02-26 30 | |
| Core EXPAREL patent formulations expired 2013-2018; earliest iovera patent expiring December 2025; competitors developing alternative delivery systems | FY2025 2026-02-26 29 | |
| Product liability exposure from EXPAREL, ZILRETTA, and iovera° use in clinical trials and commercial sale; limited $10.0 million annual aggregate insurance coverage. | FY2025 2026-02-26 29 | |
| Consolidated appeal pending for RDF declaratory judgment case regarding EXPAREL royalty obligations after December 2021 patent expiration. | FY2025 2026-02-26 29 | |
| Must maintain CGMP compliance at all manufacturing facilities; regulatory changes or enforcement could result in suspension or withdrawal of product approval. | FY2025 2026-02-26 29 | |
| FDA and EMA require additional pediatric trials for EXPAREL and clinical trials for PCRX-201 | FY2025 2026-02-26 29 | |
| Third-party payer coverage and reimbursement rates may be inadequate; 340B Drug Pricing Program expansion could increase revenue leakage | FY2025 2026-02-26 29 | |
| Securing and maintaining formulary approvals at hospitals and ASCs subject to P&T committee discretion and budget constraints. | FY2025 2026-02-26 29 | |
| Restrictions on ability to promote products beyond FDA-approved indications; regulatory enforcement risk for promotional activities. | FY2025 2026-02-26 29 | |
| Future collaboration arrangements may not be successful; termination by collaborators could adversely affect financial condition and business reputation. | FY2025 2026-02-26 29 | |
| Dependence on ability to identify, develop, acquire or in-license product candidates; uncertainty of successful integration and market adoption of new products. | FY2025 2026-02-26 29 | |
| FDA approved generic competitor to EXPAREL in July 2024 | FY2025 2026-02-26 29 | |
| Subject to federal, state and local hazardous materials and waste disposal regulations; potential penalties for non-compliance. | FY2025 2026-02-26 29 | |
| Additional funding needed for manufacturing expansion, clinical trials, product development, and debt refinancing | FY2025 2026-02-26 29 | |
| Debt financing may involve covenants restricting operations including limitations on borrowing, asset use and payment of dividends; share repurchases subject to compliance with debt agreements | FY2025 2026-02-26 29 | |
| Climate change, extreme weather and water availability challenges could disrupt manufacturing operations and supply chains; compliance with climate change regulations could increase costs | FY2025 2026-02-26 29 | |
| Pandemic or epidemic could materially adversely affect business through decreased sales, manufacturing issues, supply chain disruptions, staffing shortages and delays in customer payments | FY2025 2026-02-26 29 | |
| Competition for skilled personnel in San Francisco, San Diego, New Jersey/NYC, and Luckenwalde areas | FY2025 2026-02-26 29 | |
| Extensive federal and state healthcare regulations; anti-kickback laws, false claims liability, Medicare/Medicaid requirements | FY2025 2026-02-26 29 | |
| International regulatory approvals uncertain; timelines and requirements vary by country. | FY2025 2026-02-26 29 | |
| Complex manufacturing requirements; FDA, EMA, MHRA inspection and CGMP compliance mandatory | FY2025 2026-02-26 29 | |
| Significant competition from other pharmaceutical, medical device and biotechnology companies in pain management. | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2023-11-02 (2023-Q3), source 9 | ||
| FDA regulatory approval requirements for new indications; prior warning letter regarding EXPAREL off-label promotion | FY2025 2026-02-26 29 | |
| Inability to manufacture in sufficient quantities or maintain quality and CGMP compliance | FY2025 2026-02-26 29 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2023-08-02 (2023-Q2), source 7 | ||
| Commercial success of EXPAREL, ZILRETTA and iovera depends on market acceptance and ability to serve growing markets. | FY2025 2026-02-26 30 | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2023-08-02 (2023-Q2), source 6 | ||
| May lack sufficient cash for 2029 Note conversions or repurchases upon fundamental change; limited by Credit Agreement | FY2025 2026-02-26 29 | |
| Potential unfamiliarity with acquired companies' technology, products and markets may place company at competitive disadvantage; potential unanticipated liabilities from acquisitions may not be recoverable | FY2025 2026-02-26 29 | |
| Risks related to timing and success of clinical trials for PCRX-201 and other product candidates. | FY2025 2026-02-26 30 | |
| Pacira Biosciences: first mention in 8-K-EX99.1 earnings release of 2023-05-03 (2023-Q1), source 5 | ||
| Expect to incur additional legal costs defending intellectual property against generic manufacturers; cannot predict extent of costs or outcome. | 2026-Q1 2026-04-30 31 | |
| EXPAREL manufactured only at San Diego facility; EXPAREL and ZILRETTA at Thermo Fisher Swindon U.K.; iovera° handpieces at San Diego; iovera° Smart Tips at Amphenol Tijuana; ZILRETTA diluent at Jubilant Spokane–sole approved manufacturing sites globally. | FY2025 2026-02-26 29 | |
| Success dependent on timing and approval of FDA supplemental New Drug Applications and 510(k)s for EXPAREL, ZILRETTA and iovera. | FY2025 2026-02-26 30 | |
| Pacira Biosciences: first mention in 10-Q quarterly report of 2023-05-03 (2023-Q1), source 4 | ||
| $287.5 million 2029 Notes mature May 2029 requiring repayment or refinancing | FY2025 2026-02-26 29 | |
| Periodic litigation exposure including product liability claims and regulatory enforcement actions | FY2025 2026-02-26 29 | |
= last mention identical with the first mention (same source)
Pacira Biosciences Reported KPIs (as disclosed) (366)
NadirAlpha collects 366 reported KPIs of Pacira Biosciences from the filings up to Q2 2026; the definition comes from the company, period and source are stated at every value. NadirAlpha methodology
Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
| KPI | Value / change | Source |
|---|---|---|
| Pacira Biosciences, published 2026-08-04, period 2026-Q2 | ||
| working capital | $493.2 million | 33 |
| sales related allowances and accruals pct of gross sales | 25.2% (six months 2026), 21.7% (six months 2025) | 33 |
| revolving credit interest expense hypothetical impact | $0.8 million (100 basis point increase over 12 months) | 33 |
| iovera Smart Tip volume growth | 19% (three months), 23% (six months) | 33 |
| iovera Smart Tip net selling price decline | 2% (three months), 3% (six months) | 33 |
| gross margin | 77% (three months 2026), 77% (three months 2025), 78% (six months 2026), 79% (six months 2025) | 33 |
| diluted weighted avg shares non-GAAP | 40.3 million | 34 |
| diluted weighted avg shares GAAP | 40.3 million | 34 |
| cash and investments | 251.0 million | 34 |
| cash and equivalents and investments | $251.0 million | 33 |
| available for sale securities hypothetical rate impact | $0.1 million (100 basis point increase) | 33 |
| accumulated deficit | $191.8 million | 33 |
| ZILRETTA net selling price growth | 2% (three months), 3% (six months) | 33 |
| ZILRETTA kit volume growth | 2% (three months), 6% (six months) | 33 |
| Revolving Credit Facility outstanding | $81.0 million | 33 |
| Revolving Credit Facility all in rate | 6.72% | 33 |
| EXPAREL net selling price change | less than 1% lower | 33 |
| EXPAREL gross vial volume growth | 4% (three months), 6% (six months) | 33 |
| 2029 Notes fair value | $999 per $1,000 principal amount | 33 |
| Pacira Biosciences, published 2026-04-30, period 2026-Q1 | ||
| Working capital | 406,200 | 31 |
| Total revenues | 177,376 | 31 |
| Total net product sales | 177,376 | 31 |
| Share repurchases in | 50,000 | 31 |
| Share repurchase program authorized | 300,000 | 31 |
| Selling, general and administrative expense | 93,944 | 31 |
| Royalty revenue | – | 31 |
| Revolving Credit Facility outstanding | 86,000 | 31 |
| Revolving Credit Facility commitment amount | 300,000 | 31 |
| Research and development expense | 28,072 | 31 |
| Net product sales - iovera° | 6,176 | 31 |
| Net product sales - ZILRETTA | 26,767 | 31 |
| Net product sales - EXPAREL | 143,274 | 31 |
| Net cash used in financing activities | -59,398 | 31 |
| Net cash provided by operating activities | 25,680 | 31 |
| Net cash provided by investing activities | 19,441 | 31 |
| Interest income | 1,930 | 31 |
| Interest expense | -3,699 | 31 |
| Income tax expense | 2,082 | 31 |
| Income before income taxes | 4,998 | 31 |
| Gross margin | 79% | 31 |
| Effective tax rate | 42% | 31 |
| Diluted weighted average shares outstanding | 40.9 million | 32 |
| Cash and cash equivalents and available-for-sale investments | 202,200 | 31 |
| Cash and cash equivalents | $202.2 million | 32 |
| Accumulated deficit | -196,400 | 31 |
| 2029 Convertible Senior Notes outstanding principal | 287,500 | 31 |
| Pacira Biosciences, published 2026-02-26, period FY2025 | ||
| working capital | $427.4 million | 29 |
| Revolving credit facility outstanding | $91.0 million | 29 |
| Raw materials commitments | $9.1 million | 29 |
| Patients reached | 2.5 million | 29 |
| Lease commitments net minimum | $53.5 million | 29 |
| iovera net product sales | 7.0 million | 30 |
| iovera net product sales | 24.2 million | 30 |
| Flexion acquisition potential payments | $372.3 million | 29 |
| Convertible notes 2029 principal | $287.5 million | 29 |
| Contract manufacturing commitments | $37.2 million | 29 |
| Cash and equivalents | $238.4 million | 29 |
| accumulated deficit | $199.3 million | 29 |
| ZILRETTA net product sales | 33.0 million | 30 |
| ZILRETTA net product sales | 116.6 million | 30 |
| Shares repurchased | 5.9 million | 30 |
| Share repurchase cost | $150.0 million | 30 |
| Remaining share repurchase authorization | $150.0 million | 30 |
| Patients benefitted | 2.5 million | 30 |
| IGOR enrollment | 3,200 patients | 29 |
| Gross margin | 79% | 29 |
| EXPAREL revenue percentage | 79% | 29 |
| EXPAREL revenue percentage | 78% | 29 |
| EXPAREL revenue percentage | 80% | 29 |
| EXPAREL net product sales | 155.8 million | 30 |
| EXPAREL net product sales | 575.1 million | 30 |
| Cash and cash equivalents | 238.4 million | 30 |
| Pacira Biosciences, published 2026-01-08, period 2025-Q4 | ||
| Shares outstanding | 41.1 million | 28 |
| Share repurchases (fourth quarter) | 2.0 million shares | 28 |
| Share repurchase amount (fourth quarter) | $50.0 million | 28 |
| Remaining share repurchase authorization | $150.0 million | 28 |
| EXPAREL full-year volume growth | 6 percent | 28 |
| EXPAREL fourth quarter volume growth | 7 percent | 28 |
| Pacira Biosciences, published 2025-11-06, period 2025-Q3 | ||
| working capital | $455.7 million | 26 |
| Share repurchase program purchases | $100.1 million | 26 |
| Share repurchase program authorized | $300.0 million | 26 |
| Revolving credit facility outstanding | $96.0 million | 26 |
| Revolving credit facility commitment | $300.0 million | 26 |
| cash and equivalents and investments | $246.3 million | 26 |
| accumulated deficit | $201.0 million | 26 |
| Total cash, cash equivalents and available-for-sale investments | 246.3 | 27 |
| Short-term available-for-sale investments | 98.7 | 27 |
| EXPAREL patents in Orange Book | 21 | 26 |
| Diluted weighted average shares outstanding (Non-GAAP) | 45.4 | 27 |
| Diluted weighted average shares outstanding (GAAP) | 44.5 | 27 |
| Cash and cash equivalents | 147.6 | 27 |
| 2029 convertible notes outstanding | $287.5 million | 26 |
| Pacira Biosciences, published 2025-08-05, period 2025-Q2 | ||
| iovera° net product sales | 5.6 million | 25 |
| iovera revenue | 5,588 | 24 |
| iovera revenue 6M | 10,711 | 24 |
| ZILRETTA revenue | 31,334 | 24 |
| ZILRETTA revenue 6M | 54,672 | 24 |
| ZILRETTA net product sales | 31.3 million | 25 |
| Working capital | 432.4 million | 24 |
| Total stockholders' equity | 757.8 million | 25 |
| Total revenues | 181,099 | 24 |
| Total revenues 6M | 350,022 | 24 |
| Total revenues | 181.1 million | 25 |
| Total net product sales | 180,347 | 24 |
| Total net product sales 6M | 347,941 | 24 |
| Short-term available-for-sale investments | 145.4 million | 25 |
| SG&A expense | 88,578 | 24 |
| SG&A expense 6M | 175,354 | 24 |
| R&D expense | 28,200 | 24 |
| R&D expense 6M | 53,893 | 24 |
| Operating cash flow 6M | 47,471 | 24 |
| Operating cash flow 6M | 102,337 | 24 |
| Investing cash flow 6M | 36,534 | 24 |
| Gross margin | 77% | 24 |
| Gross margin 6M | 79% | 24 |
| Financing cash flow 6M | -60,499 | 24 |
| EXPAREL revenue | 142,917 | 24 |
| EXPAREL revenue 6M | 279,446 | 24 |
| EXPAREL net product sales | 142.9 million | 25 |
| Diluted weighted average shares outstanding | 45.5 million | 25 |
| Cost of goods sold | 40,866 | 24 |
| Cost of goods sold 6M | 75,172 | 24 |
| Cash and investments | 445.9 million | 24 |
| Cash and cash equivalents | 300.5 million | 25 |
| Accumulated deficit | 206.4 million | 24 |
| Pacira Biosciences, published 2025-05-08, period 2025-Q1 | ||
| iovera° net product sales | 5.1 million | 23 |
| ZILRETTA net product sales | 23.3 million | 23 |
| Total revenues | 168.9 million | 23 |
| EXPAREL net product sales | 136.5 million | 23 |
| EXPAREL average daily volume growth | 7% | 23 |
| Cash provided by operations | 35.5 million | 23 |
| Cash and cash equivalents | 283.610 million | 23 |
| Pacira Biosciences, published 2025-02-27, period FY2024 | ||
| working capital | $435.2 million | 20 |
| pMVL patent families | >13 | 20 |
| outstanding principal TLA Term Loan | $105.3 million | 20 |
| outstanding principal 2029 Notes | $287.5 million | 20 |
| outstanding principal 2025 Notes | $202.5 million | 20 |
| net minimum lease commitments | $64.0 million | 20 |
| minimum contractual commitments raw materials | $6.5 million | 20 |
| minimum contractual commitments contract manufacturing | $59.9 million | 20 |
| iovera patent families | 29 | 20 |
| iovera net product sales | $22.8 million | 20 |
| iovera net product sales | $19.7 million | 20 |
| iovera net product sales | $15.3 million | 20 |
| iovera TKA pain score reduction | 22% | 20 |
| iovera TKA opioid use at 6 weeks cryoanalgesia group | 14% | 20 |
| iovera TKA opioid use at 6 weeks control group | 44% | 20 |
| iovera TKA morphine equivalent reduction 72 hours | 51% | 20 |
| iGOR registry participating sites | 12 | 20 |
| iGOR registry enrollment as of November | >2,000 | 20 |
| cash and cash equivalents and available for sale investments | $484.6 million | 20 |
| accumulated deficit | $206.4 million | 20 |
| ZILRETTA patent families | 2 | 20 |
| ZILRETTA net product sales | $118.1 million | 20 |
| ZILRETTA net product sales | $111.1 million | 20 |
| ZILRETTA net product sales | $105.5 million | 20 |
| Women opioid dependency risk vs men | 40% more likely | 20 |
| Women OA diabetes comorbidity | 14% | 20 |
| Warehouse square footage | 21,000 | 20 |
| Third molar procedures annual US | 5 million | 20 |
| Third molar extraction placebo refill rate | 7.7% | 20 |
| Third molar extraction EXPAREL refill rate | 3.3% | 20 |
| Third molar extraction EXPAREL opioid reduction | 59% | 20 |
| Science Center Campus square footage | 195,000 | 20 |
| Science Center Campus acreage | 5 | 20 |
| Research development manufacturing office facility square footage | 90,000 | 20 |
| RDF expected recovery amount | $14.5 million | 20 |
| Pediatric moderate severe pain hospitalization | 50% | 20 |
| Pediatric chronic pain | 20% | 20 |
| PCRX 201 Phase 1 treatment related joint effusions pretreated | 36% | 20 |
| PCRX 201 Phase 1 treatment related joint effusions not pretreated | 61% | 20 |
| PCRX 201 Phase 1 stiffness improvement pretreated cohort low | 53% | 20 |
| PCRX 201 Phase 1 stiffness improvement pretreated cohort high | 72% | 20 |
| PCRX 201 Phase 1 participants greater than 50 percent pain reduction by 16 weeks | >70% | 20 |
| PCRX 201 Phase 1 pain reduction pretreated cohort low | 48% | 20 |
| PCRX 201 Phase 1 pain reduction pretreated cohort high | 65% | 20 |
| PCRX 201 Phase 1 effusions median resolution days | 33 | 20 |
| Osteoarthritis prevalence US | 32.5 million | 20 |
| Medicaid tooth extraction opioid prescriptions | 1.2 million | 20 |
| Medicaid tooth extraction opioid prescription rate | 42% | 20 |
| Medicaid median morphine equivalent per patient | 120 | 20 |
| McKesson revenue percentage | 34% | 20 |
| Lower extremity procedures annually | 3 million | 20 |
| Knee OA symptomatic individuals US | 14 million | 20 |
| Knee OA lifetime risk | 45% | 20 |
| Knee OA individuals under 45 US | 2 million | 20 |
| GQ Bio ownership acquired February | 81% | 20 |
| GQ Bio Milestone 3 payment | €0.5 million | 20 |
| GQ Bio Milestone 2 success fee minimum | €0.5 million | 20 |
| GQ Bio Milestone 2 success fee maximum | €7.5 million | 20 |
| GQ Bio Milestone 2 royalty minimum | 0.25% | 20 |
| GQ Bio Milestone 2 royalty maximum | 3.75% | 20 |
| GQ Bio Milestone 1 payment | €0.5 million | 20 |
| Flexion Acquisition initial consideration | $578.8 million | 20 |
| Flexion Acquisition debt settlement | $85.1 million | 20 |
| Flexion Acquisition contingent value rights maximum | $372.3 million | 20 |
| Flexion Acquisition contingent consideration | $45.2 million | 20 |
| Flexion Acquisition cash to shareholders | $448.5 million | 20 |
| EXPAREL revenue percentage | 78% | 20 |
| EXPAREL revenue percentage | 80% | 20 |
| EXPAREL revenue percentage | 81% | 20 |
| EXPAREL net product sales | $549.0 million | 20 |
| EXPAREL net product sales | $538.1 million | 20 |
| EXPAREL net product sales | $536.9 million | 20 |
| EXPAREL manufacturing facility square footage | 84,000 | 20 |
| EXPAREL Phase 3 sciatic popliteal opioid free subjects | statistically significant reduction | 20 |
| EXPAREL Phase 3 sciatic popliteal opioid consumption reduction | statistically significant reduction | 20 |
| EXPAREL Phase 3 sciatic popliteal cumulative pain reduction | statistically significant reduction | 20 |
| EXPAREL Phase 3 interscalene pain score reduction | 46% | 20 |
| EXPAREL Phase 3 interscalene opioid free 48 hours | 13% | 20 |
| EXPAREL Phase 3 interscalene opioid consumption reduction | 78% | 20 |
| EXPAREL Phase 3 hemorrhoidectomy placebo no opioid through 72 hours | 10% | 20 |
| EXPAREL Phase 3 hemorrhoidectomy patients no opioid through 72 hours | 28% | 20 |
| EXPAREL Phase 3 hemorrhoidectomy opioid reduction | 45% | 20 |
| EXPAREL Phase 3 hemorrhoidectomy median time to opioid rescue placebo | 1 hour | 20 |
| EXPAREL Phase 3 hemorrhoidectomy median time to opioid rescue EXPAREL | 15 hours | 20 |
| EXPAREL Phase 3 adductor canal opioid consumption reduction | statistically significant reduction | 20 |
| EXPAREL Phase 3 adductor canal cumulative pain reduction | statistically significant reduction | 20 |
| Chronic back pain interventional procedures | 2 to 3 million | 20 |
| Chronic back pain annual treatment seekers US | 28 to 30 million | 20 |
| Cardiothoracic surgery persistent pain | 35% | 20 |
| Cardiothoracic opioid use over 90 days | ~10% | 20 |
| Cardinal Health revenue percentage | 23% | 20 |
| Aratana commercial milestones | $40.0 million | 20 |
| Annual pediatric procedures US | 1 million | 20 |
| AmerisourceBergen revenue percentage | 20% | 20 |
| Pacira Biosciences, published 2025-02-27, period 2024-Q4 | ||
| Cash and cash equivalents | $484.6 million | 21 |
| Pacira Biosciences, published 2025-01-10, period 2024-Q4 | ||
| Selling days | 249 in 2024, 250 in 2023 | 19 |
| Patients treated per year | More than three million | 19 |
| EXPAREL average daily volume growth | 4 percent | 19 |
| Pacira Biosciences, published 2024-11-06, period 2024-Q3 | ||
| working capital | 383.6 million | 17 |
| Total revenues 9M | 513,713 | 17 |
| Total revenues 3M | 168,573 | 17 |
| Total net product sales 9M | 509,933 | 17 |
| Total net product sales 3M | 167,722 | 17 |
| iovera° net product sales | 5.7 million | 18 |
| iovera revenue 9M | 16,359 | 17 |
| iovera revenue 3M | 5,655 | 17 |
| Gross margin 9M | 75% | 17 |
| Gross margin 3M | 77% | 17 |
| cash and equivalents and investments | 453.8 million | 17 |
| accumulated deficit | 222.4 million | 17 |
| ZILRETTA revenue 9M | 84,966 | 17 |
| ZILRETTA revenue 3M | 28,420 | 17 |
| ZILRETTA net product sales | 28.4 million | 18 |
| Weighted average shares outstanding | 46.134 million | 18 |
| Total revenues | 168.6 million | 18 |
| Total cash position | 453.8 million | 18 |
| Short-term available-for-sale investments | 207.845 million | 18 |
| Non-GAAP diluted weighted average shares outstanding | 48.971 million | 18 |
| EXPAREL revenue 9M | 401,286 | 17 |
| EXPAREL revenue 3M | 132,004 | 17 |
| EXPAREL net product sales | 132.0 million | 18 |
| Cash and cash equivalents | 245.965 million | 18 |
| Pacira Biosciences, published 2024-07-30, period 2024-Q2 | ||
| Working capital | 539.5 million | 15 |
| Total selling, general and administrative expense 6M | 140,152 | 15 |
| Total selling, general and administrative expense 3M | 68,126 | 15 |
| Total revenues 6M | 345,140 | 15 |
| Total revenues 3M | 178,023 | 15 |
| Total research and development expense 6M | 38,576 | 15 |
| Total research and development expense 3M | 20,338 | 15 |
| Total net product sales 6M | 342,211 | 15 |
| Total net product sales 3M | 176,387 | 15 |
| TLA Term Loan principal outstanding | 110.9 million | 15 |
| Stock-based compensation SG&A 6M | 16,833 | 15 |
| Stock-based compensation SG&A 3M | 8,848 | 15 |
| Stock-based compensation R&D 6M | 3,728 | 15 |
| Stock-based compensation R&D 3M | 1,925 | 15 |
| Sales and marketing 6M | 78,482 | 15 |
| Sales and marketing 3M | 39,047 | 15 |
| Royalty revenue 6M | 2,929 | 15 |
| Royalty revenue 3M | 1,636 | 15 |
| Restructuring charges 6M | 6,531 | 15 |
| Restructuring charges 3M | 996 | 15 |
| Regulatory and other 6M | 5,617 | 15 |
| Regulatory and other 3M | 2,923 | 15 |
| Product development and manufacturing capacity expansion 6M | 14,713 | 15 |
| Product development and manufacturing capacity expansion 3M | 7,318 | 15 |
| Operating cash flow | $53.2 million | 16 |
| Net product sales iovera 6M | 10,704 | 15 |
| Net product sales iovera 3M | 5,674 | 15 |
| Net product sales ZILRETTA 6M | 56,546 | 15 |
| Net product sales ZILRETTA 3M | 30,707 | 15 |
| Net product sales EXPAREL 6M | 269,282 | 15 |
| Net product sales EXPAREL 3M | 136,852 | 15 |
| Net product sales Bupivacaine 6M | 5,679 | 15 |
| Net product sales Bupivacaine 3M | 3,154 | 15 |
| Net increase in cash and cash equivalents | 93,755 | 15 |
| Interest income 6M | 8,652 | 15 |
| Interest income 3M | 4,749 | 15 |
| Interest expense 6M | -7,200 | 15 |
| Interest expense 3M | -3,884 | 15 |
| Income tax expense 6M | 22,359 | 15 |
| Income tax expense 3M | 17,698 | 15 |
| Gross margin 6M | 73 % | 15 |
| Gross margin 3M | 75 % | 15 |
| General and administrative 6M | 44,837 | 15 |
| General and administrative 3M | 20,231 | 15 |
| Gain on early extinguishment of debt 6M | 7,518 | 15 |
| Gain on early extinguishment of debt 3M | 7,518 | 15 |
| Flexion contingent consideration 6M | -2,297 | 15 |
| Flexion contingent consideration 3M | 1,509 | 15 |
| Effective tax rate 6M | 45 % | 15 |
| Effective tax rate 3M | 48 % | 15 |
| Diluted weighted average shares outstanding | 50.5 million | 16 |
| Cost of goods sold 6M | 91,678 | 15 |
| Cost of goods sold 3M | 44,262 | 15 |
| Clinical and preclinical development 6M | 14,518 | 15 |
| Clinical and preclinical development 3M | 8,172 | 15 |
| Cash from operating activities | 102,337 | 15 |
| Cash from investing activities | -30,745 | 15 |
| Cash from financing activities | 22,163 | 15 |
| Cash and cash equivalents and available for sale investments | 404.2 million | 15 |
| Cash and cash equivalents | $404.2 million | 16 |
| Basic weighted average shares outstanding | 46.2 million | 16 |
| Acquisition related expenses 6M | 404 | 15 |
| Acquisition related expenses 3M | 230 | 15 |
| Accumulated deficit | -78.9 million | 15 |
| 2029 Notes principal outstanding | 287.5 million | 15 |
| 2025 Notes principal outstanding | 202.5 million | 15 |
| Pacira Biosciences, published 2024-05-07, period 2024-Q1 | ||
| working capital | 449.7 million | 13 |
| iovera° net product sales | 5.0 million | 14 |
| gross margin | 72 % | 13 |
| Cash and cash equivalents and investments | 325.9 million | 13 |
| accumulated deficit | 97.8 million | 13 |
| ZILRETTA net product sales | 25.8 million | 14 |
| Total revenues | 167.1 million | 14 |
| TLA Term Loan principal outstanding | 113.8 million | 13 |
| Flexion 2024 Notes principal outstanding | 8.6 million | 13 |
| EXPAREL net product sales | 132.4 million | 14 |
| Diluted weighted average shares outstanding | 52.2 million | 14 |
| Cash, cash equivalents and available-for-sale investments | 325.9 million | 14 |
| Cash provided by operations | 49.1 million | 14 |
| Basic weighted average shares outstanding | 46.5 million | 14 |
| 2025 Notes principal outstanding | 402.5 million | 13 |
| Pacira Biosciences, published 2024-02-29, period 2023-Q4 | ||
| EXPAREL patient mark | 14 million | 12 |
| Cash and cash equivalents | $281.0 million | 12 |
| Pacira Biosciences, published 2024-01-04, period FY2023 | ||
| EXPAREL average daily volume growth full year | 5 percent | 10 |
| EXPAREL average daily volume growth Q4 | 4 percent | 10 |
| Pacira Biosciences, published 2023-11-02, period 2023-Q3 | ||
| working capital | $353.6 million | 8 |
| cash and cash equivalents and available for sale investments | $235.2 million | 8 |
| accumulated deficit | $131.7 million | 8 |
| Cash provided by operations | $44.4 million | 9 |
| Cash and cash equivalents | $235.2 million | 9 |
| Pacira Biosciences, published 2023-08-02, period 2023-Q2 | ||
| Working capital | 320.4 million | 6 |
| Total cash | 220.8 million | 7 |
| TLA Term Loan outstanding principal | 147.2 million | 6 |
| Patients treated with EXPAREL since initial approval in | more than 12 million | 6 |
| OA affects in the U.S. | over 32.5 million adults | 6 |
| Lifetime risk of developing symptomatic knee OA | 45 percent | 6 |
| Individuals under age 45 with symptomatic knee OA | nearly two million | 6 |
| Individuals in the U.S. with symptomatic knee OA | 14 million | 6 |
| Flexion 2024 Notes outstanding principal | 8.6 million | 6 |
| Fair value of 2025 Notes | 926 per $1,000 principal amount | 6 |
| Cash provided by operations | 43.5 million | 7 |
| Cash provided by operations | 29.8 million | 7 |
| Cash and cash equivalents and available-for-sale investments | 220.8 million | 6 |
| Cash and cash equivalents | 86,810 | 7 |
| Available-for-sale investments (short-term) | 133,956 | 7 |
| Accumulated deficit | -142.5 million | 6 |
| 2025 Notes outstanding principal | 402.5 million | 6 |
| Pacira Biosciences, published 2023-05-03, period 2023-Q1 | ||
| Total cash and investments | 182.3 | 5 |
| Cash provided by operations | 19.1 | 5 |
| Cash and cash equivalents | 35,545 | 5 |
| Available-for-sale investments (short-term) | 138,454 | 5 |
| Available-for-sale investments (noncurrent) | 8,281 | 5 |
Pacira Biosciences Development
The business development of Pacira Biosciences period by period up to Q2 2026, each text from the original report of that period, source numbers lead to the source. NadirAlpha methodology
FY2026: Pacira Biosciences
Pacira Biosciences posted total revenues of USD 177.4 million in Q1 2026 and USD 192.4 million in Q2 2026, with 5% and 6% year-over-year growth in each quarter driven by volume gains across EXPAREL, ZILRETTA and iovera° 32 34. Pacira Biosciences divested iovera° to Zimmer Biomet on July 31, 2026 for $73.6 million upfront plus potential milestone payments up to $70 million through 2031, concentrating the portfolio on EXPAREL and the pipeline 33. Net debt declined from USD 223.3 million at the end of Q1 to USD 157.2 million at the end of Q2, supported by higher operating cash flow in the second quarter 33. PCRX-201 received Regenerative Medicine Advanced Therapy designation from the FDA and Advanced Therapy Medicinal Products designation from the EMA, and enrollment in the Phase 2 ASCEND study advanced through the first half of 2026 31. Full-year 2026 guidance for EXPAREL net product sales of $600 to $620 million and total revenues of $745 to $770 million was reiterated following Q1 results 32.
FY2025: Pacira Biosciences
Pacira Biosciences reported total revenues of $726.4 million in fiscal year 2025, a 4% increase from $701.0 million in 2024, with EXPAREL net product sales rising 5% to $575.1 million on 6% gross vial volume growth 29. ZILRETTA net product sales declined 1% to $116.6 million due to a 4% volume decrease, while iovera° grew 6% to $24.2 million on 7% Smart Tip volume growth 29. Full-year gross margin expanded to 79% from 76% in 2024, described as the highest level in the company's history, driven by lower EXPAREL inventory reserves and improved ZILRETTA product costs from higher manufacturing volumes, partially offset by accelerated depreciation from decommissioning of the 45-liter manufacturing suite 29 30. Full-year GAAP net income reached $7.0 million compared to a net loss of $99.6 million in 2024; the prior-year loss reflected a $163.2 million goodwill impairment triggered by FDA approval of a generic EXPAREL competitor and a patent invalidation ruling 29. Key strategic developments included the launch of the 5x30 growth plan targeting three million patients annually by 2030, the acquisition of GQ Bio Therapeutics GmbH consolidating the PCRX-201 gene therapy program, a co-promotion agreement with Johnson & Johnson MedTech for ZILRETTA, and completion of Phase 2 Part A enrollment for PCRX-201 in knee osteoarthritis 29.
FY2024: Pacira Biosciences
Pacira BioSciences generated FY2024 total revenues of $701.0 million, a 4% increase from $675.0 million in 2023, with EXPAREL net product sales of $549.0 million (+2%), ZILRETTA of $118.1 million (+6%), and iovera° of $22.8 million (+16%) 21. Full-year gross margin improved to 76% from 73% and adjusted EBITDA grew 4% to $223.9 million, while operating cash flow rose to $189.4 million from $154.6 million in the prior year 21. The GAAP result was a net loss of $99.6 million, driven by a $163.2 million non-cash goodwill impairment charge recorded in Q3 2024 following FDA approval of a generic EXPAREL competitor in July 2024 and a U.S. District Court ruling invalidating one EXPAREL patent in August 2024 20 21. In November 2024, CMS confirmed that both EXPAREL and iovera° qualify for separate Medicare reimbursement under the NOPAIN Act effective January 1, 2025, and earlier in the year PCRX-201 received FDA Regenerative Medicine Advanced Therapy designation as the first gene therapy candidate for osteoarthritis 20. In January 2025, the company announced a five-year 5x30 strategic plan targeting double-digit revenue CAGR and treatment of more than three million patients annually by 2030 19.
FY2023: Pacira Biosciences
Pacira BioSciences reported full-year 2023 total revenue of $675.0 million, a 1% increase from $666.8 million in 2022, with growth across all three product lines 10. EXPAREL net product sales reached $538.1 million, growing approximately 5% on average daily volume, though enrollment in the 340B Drug Pricing Program and expanded contracted relationships weighed on net selling prices throughout the year 11. ZILRETTA contributed $111.1 million (up 5.3%) and iovera° $19.7 million (up 28.4%) to full-year net product sales 10. Gross margin improved three percentage points to 73% in 2023, primarily due to lower inventory reserves and reduced royalty expense compared to 2022, partially offset by EXPAREL price pressure from increased 340B discounting 11. Full-year GAAP net income reached $42.0 million ($0.89 diluted EPS) and operating cash flow was $154.6 million; in November 2023 the FDA approved an EXPAREL label expansion for lower extremity nerve block indications, and in March 2023 the company replaced a $287.5 million term loan with a $150.0 million facility at an interest rate 400 basis points lower 11 12 4.
Glossary
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- EBITDA (adj.): Adjusted EBITDA, verbatim and company-defined (non-GAAP), never derived.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- EPS adj.: Adjusted earnings per share, verbatim and company-defined (non-GAAP).
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: quarterly reports, annual reports and investor relations documents
The evidence base for Pacira Biosciences stock: every document with type and date, every figure in the report leads here by number and to the original by link. NadirAlpha methodology
53 documents · 2016 to 2026 · SEC EDGAR (USA)
Older sources (+19)
| # | Document type | Published |
|---|---|---|
| #202 | 10-K annual report | 2016-05-02 |
| #201 | 10-Q quarterly report | 2016-08-04 |
| #204 | 10-K annual report | 2017-03-01 |
| #208 | 10-K annual report | 2017-03-01 |
| #203 | 10-Q quarterly report | 2017-08-02 |
| #212 | 10-K annual report | 2018-02-28 |
| #205 | 10-Q quarterly report | 2018-05-03 |
| #206 | 10-Q quarterly report | 2018-08-02 |
| #207 | 10-Q quarterly report | 2018-11-01 |
| #216 | 10-K annual report | 2019-02-28 |
| #209 | 10-Q quarterly report | 2019-05-02 |
| #210 | 10-Q quarterly report | 2019-08-08 |
| #211 | 10-Q quarterly report | 2019-11-08 |
| #213 | 10-Q quarterly report | 2020-05-07 |
| #214 | 10-Q quarterly report | 2020-08-06 |
| #215 | 10-Q quarterly report | 2020-10-30 |
| #217 | 10-Q quarterly report | 2021-05-04 |
| #218 | 10-Q quarterly report | 2021-08-03 |
| #219 | 10-Q quarterly report | 2021-11-03 |
Pacira Biosciences Stock FAQ
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Which additional key figures does Pacira Biosciences report?
As reported for Q2 2026: ZILRETTA net selling price growth, ZILRETTA kit volume growth, EXPAREL net selling price change, EXPAREL gross vial volume growth. The chapter Reported KPIs lists every value with its source. Revenue is broken down by ZILRETTA, iovera°, EXPAREL.
Where can I find the official investor relations documents of Pacira Biosciences?
NadirAlpha links all 53 original filings used (SEC filings) in the sources chapter: earnings release, quarterly report, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.